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i. Abstract: 
  
Genomic instability and a high mutation rate lead to heterogeneity in human 
tumors. Mathematical modelling predicts that these characteristics promote 
acquired resistance to cytotoxic and targeted therapies, by increasing the likelihood 
that resistant subpopulations exist at the start of treatment (and promoting the 
accumulation of de novo resistance mutations during treatment).  As a result, 
genome plasticity promotes increased fitness on the population level, but individual 
tumor cells must nonetheless maintain a level of DNA integrity that allows for 
continued survival, particularly in the context of DNA-damaging therapy (which 
DNA repair counteracts). Thus, DNA repair proteins are a source of innate 
resistance to many common anti-cancer drugs, and represent intriguing targets for 
therapeutic attack.  
One way to forestall treatment resistance is to sensitize tumor cells to DNA-
damaging therapy by inhibiting DNA repair and decreasing survival following drug 
treatment. I developed the concept of complementary lethality, defined as 
“potentiation of drug therapy by the inhibition of DNA repair factors responsible for 
resistance to that specific drug”. BRCA2 is involved in homologous recombination 
repair (HRR) of double stranded breaks (DSBs) in DNA, and mutations in the 
BRCA2 gene predispose to various cancers. However, patients with BRCA2-
mutated tumors respond more favourably to some types of therapy. I found that 
inhibition of BRCA2 with siRNA sensitized tumor cells to DNA-damaging drugs and 
thus overcame innate resistance to their action. Combined inhibition of BRCA2 and 
thymidylate synthase (TS), the enzyme responsible for de novo synthesis of 
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thymidylate (and the source of innate resistance to several treatments), rendered 
tumor cells responsive to a broader range of drugs and created a state of multi-
drug sensitivity.  
Based on these results, I created a novel BRCA2-targeting antisense 
oligodeoxynucleotide (ASO) and tested it in the context of cisplatin treatment. 
ASOs exhibit several advantages over siRNAs in vivo, and some ASO-based drugs 
have been approved by the FDA.   I found that BRCA2 downregulation (with the 
BRCA2 ASO) enhanced the ability of cisplatin (a cytotoxic, DNA-damaging drug) 
to control tumor cell proliferation in vitro and metastasis in vivo, and also induced 
alterations in cellular metabolism.  
Further studies using the PARP-1 inhibitor olaparib, which is selectively 
lethal in cells with HRR deficiency, led me to formulate the concept of “reciprocal 
positive selection for weakness”: in a population heterogeneous for HRR-
proficiency, olaparib selects for HRR-proficient cells, while BRCA2 inhibition 
selects for HRR-deficient cells. Each individual treatment thus selects for cells 
‘weak’ to the other in a reciprocal manner, and combined inhibition of both targets 
should prevent selection-mediated escape. This is a strategy that aims to prevent 
acquired resistance in a heterogeneous tumor population by nullifying enrichment 
of specific cell subpopulations.  
I found that BRCA2 inhibition can render HRR-positive cancer cells (with 
innate resistance to olaparib) sensitive to PARP inhibition. Furthermore, olaparib 
monotherapy in a primarily HRR-deficient mixed cell population (3:1 ratio of HRR-
deficient:HRR-proficient cells) induced resistance to further olaparib treatment 
after just one dose. This parallels clinical reports which show that patients with 
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BRCA2-mutated tumors can present with tumors harboring functional BRCA2 
protein following olaparib therapy, presumably due to treatment-mediated selection 
of subclones present at the start of therapy. In my experiments, co-treatment of 
this same mixed population with BRCA2 ASO and olaparib prevented enrichment 
based on HRR-proficiency and eliminated the tumor cell population. In addition, 
treatment of ovarian tumor-bearing mice with BRCA2 siRNA and olaparib in vivo 
decreased both the number and weight of tumor nodules when compared with 
each treatment individually. These studies highlight the important role that DNA 
repair mediators such as BRCA2 play in innate and acquired resistance to 
treatment, and provide rationale for therapeutic targeting of DNA repair in human 
tumors.  
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Chapter 1. Introduction: 
 
1.1 The hallmarks of human tumor cells 
 As a result of random mutagenesis and/or genetic predisposition reinforced 
by Darwinian selection pressures, human cells acquire a variety of interconnected 
biological traits (or “hallmarks of cancer”) as they progress through malignant 
transformation into tumor cells [1]. These characteristics, constituting 
complementary changes in cell physiology, result in highly plastic, immortal and 
invasive cells which form tumors and cause disease in the host.  
According to Hanahan’s seminal review, one fundamental hallmark of a 
tumor cell is the ability to sustain and react to proliferative signalling [1].  This 
manifests through different mechanisms, including activating mutations in positive 
regulators of cell growth (such as the serine/threonine-protein kinase BRAF), which 
allow constitutive proliferative signalling [2].   
By extension, cell cycle control and growth inhibition pathways which 
negatively regulate proliferation are also frequently mutated in tumor cells. 
Alterations in prototypical growth suppressors, such as tumor protein 53 (TP53) 
and retinoblastoma protein (pRB), facilitate an override of powerful monitoring and 
signalling networks that negatively regulate proliferation [1, 3]. TP53, which is 
mutated in a high proportion of human cancers, is normally responsible for 
responding to DNA damage, inappropriate growth signals, nucleotide pool 
availability, and other intracellular stressors, and can induce signalling events 
which delay cell cycle progression or promote apoptosis [4].  
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 Apoptosis functions to prevent the survival of abnormal cells. Thus, avoiding 
apoptosis is another hallmark of cancer, and complements the ability to maintain 
uncontrolled proliferation. Tumor cells often exhibit further alterations (in addition 
to TP53) in pro- and anti- apoptotic mediators which collectively decrease 
susceptibility to programmed cell death and allow continued replication [5]. 
Telomeres, which function to protect chromosomes from deterioration, are 
normally shortened with each cell division, and serve to limit the total amount of 
replicative cycles in a cell. Telomerases are enzymes which can increase telomere 
length, and though virtually inactive in non-immortalized cells, up to 90% of tumor 
cells exhibit telomerase activity; this removes the normal limits on DNA replication 
and enables replicative immortality [1, 6]. 
 Tumor cells develop the qualities described above, as well as other 
hallmarks (e.g., invasion and metastasis, evasion of the immune system, etc.) 
which allow for self-renewal, and support the creation of self-sustaining tumor 
masses. However, underlying all of these traits is a level of genomic plasticity and 
diversity that allows for continued mutation, adaptation, and response to selection 
pressures. This can be considered a ‘unifying’ hallmark of cancer, and the majority 
of human tumor cells exhibit a high mutation frequency and/or chromosomal 
instability, which facilitates the stochastic acquisition of malignant traits. On the 
population level, the inherent mutability of individual tumor cells creates a diverse 
ecosystem complete with polyclonal adaptability, phenotype and genotype 
variability, and constant competition for survival based on intrinsic and extrinsic 
selection pressures. In this context, the fit survive while the weak do not, and it is 
in this multifaceted biome that anti-cancer treatments must function and succeed.   
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1.2 Tumor heterogeneity and therapeutic resistance 
A high degree of heterogeneity is a common feature of human tumors, and 
presents a significant obstacle for successful therapy. This complex genetic and 
phenotypic mosaic is determined to a large extent by accumulation of chromosome 
abnormalities (e.g., breaks, exchanges, duplications, etc.) and alterations in 
mutational load throughout the dynamic evolution of a tumor [7, 8]. Single-nucleus 
exome sequencing of breast cancer samples has revealed that no individual 
cancer cell in a tumor is genetically identical [9], and highlights one of the critical 
challenges to successful anti-cancer treatment: preventing and overcoming innate 
and acquired therapeutic resistance in a polyclonal tumor ecosystem.   
Given this high degree of intratumor diversity, it is highly likely that a 
population of resistant cells exists in a tumor at the start of any therapy [10, 11]. 
For example, hundreds of individual clones have been identified in the HCC827 
lung cancer cell line with pre-existing resistance to erlotinib (EGFR inhibitor). In the 
same series of experiments, dozens of clones with dual resistance to both erlotinib 
and crizotinib (ALK-EML fusion inhibitor) were also isolated [10]. This suggests that 
any given tumor cell population may contain a detectable number of  subclones 
with pre-existing resistance mutations, thus rendering the probability of treatment 
failure extraordinarily high, and partly explains why overall survival is rarely 
improved following therapy.   
Alternatively, the high mutation rate present in a significant proportion of 
tumor cells drastically increases the likelihood of resistance through de novo 
mutations during the course of treatment [11]. This is more probable if the 
treatment is slow acting (i.e., acts over a time frame that facilitates DNA replication 
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and/or repair) because it allows more time for potentially deleterious mutations to 
develop [12]. However, these scenarios (pre-existing versus newly-arising 
mutations which lead to resistance) are not mutually exclusive, can both lead to 
therapeutic failure, and were proposed and discussed in the scientific literature as 
early as 1957 [13] (Figure 1). 
Mathematical modeling based on melanoma patient responses to the BRAF 
inhibitor vemurafenib (which targets the common V600E mutation [14]), illustrate 
the relationship between mutation rate, tumor size, and drug resistance. According 
to the algorithm, it is a mathematical certainty that a tumor population will become 
resistant to vemurafenib if the tumor is of sufficient size and exhibits a high mutation 
rate [12]. This maximizes the probability that resistant subpopulations will exist at 
the start of treatment. If the therapy is slow acting, then a high mutation rate 
increases the probability of de novo resistance mutations arising during treatment. 
A similar relationship to that described for melanoma has been identified in the 
development of colon cancer cell resistance to erlotinib treatment [15]. Therefore, 
targeted molecular drugs such as vemurafenib and, by extension, general cytotoxic 
drugs such as cisplatin, are predicted to fail with a very high probability, and this 
prediction has proven to be true in clinical practice [16, 17]. Combination therapy 
decreases the likelihood of resistance, but is still a function of tumor size and the 
speed with which the therapy debulks the tumor mass [12].  
Therefore, designing therapeutic approaches to overcome the inherent 
challenge of tumor heterogeneity-driven resistance is crucial to improve efficacy 
and patient outcome. One strategy, which will be described in the section 1.4, is to 
rationally (based on known function and predicted outcome) inhibit specific 
5 
 
  
Selection for 
pre-existing 
resistant clones
Stochastic 
emergence of 
resistant clones
Treatment 
sensitive clones
TREATMENT
Treatment 
resistant clones
Figure 1 – Therapeutic resistance in heterogeneous tumor cell populations. In a 
given tumor mass with a large enough size and mutation rate, it is highly likely that 
resistant cells pre-exist at the start of treatment. For instance, the resistant cells may 
express a DNA repair protein like BRCA2 at high levels, which renders them less 
responsive to DNA-damaging therapy. The sensitive cells (e.g., BRCA2 deficient), 
which make up the majority of the population, are eliminated by treatment and the 
resistant cells re-populate the tumor, leading to therapeutic failure. However, it is also 
possible that stochastic emergence of resistant cells occurs as a result of random 
mutagenesis during the treatment process. This is more likely to occur if the treatment 
is slow acting.   
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mediators of DNA repair and combine these treatments with chemotherapeutic 
drugs that kill or inhibit tumor cell replication by damaging DNA. The aim is to 
sensitize tumor cells to treatment by overcoming DNA repair-mediated, innate 
resistance to therapy, and decrease the probability of tumor cell survival following 
treatment.  A second approach, described in section 1.5, is to combine inhibition 
of specific DNA repair mediators in a manner that exploits their functional inter-
dependence and renders acquired resistance more unlikely in a heterogeneous 
tumor population by selecting for ‘weakness’ instead of ‘fitness’.   
 
1.3 Genome plasticity, DNA repair, and cancer treatment 
 A significant proportion of solid tumors exhibit a high mutational rate and/or 
chromosomal instability (CIN), which contribute to tumor heterogeneity and thus 
increase the fitness of a tumor cell population and the incidence of therapeutic 
resistance [18]. However, these same characteristics can act as an “Achilles’ heel’ 
for individual tumor cells which mutate past a tolerable threshold and reach a level 
of DNA or chromosomal instability that is no longer compatible with survival [19]. 
It is well established that mutations in DNA repair proteins such as BRCA1 
or BRCA2 lead to an increased risk of developing breast, ovarian, and other 
cancers [20]. Compromised homologous recombination repair (HRR) capacity 
leads to higher mutational load and chromosomal instability that promotes 
malignant transformation and tumor development [21]. However, even though 
individuals with BRCA2 mutations exhibit increased cancer incidence, patients with 
BRCA2-mutated tumors respond more favourably to therapy than those with 
sporadic (non-BRCA2 related) cancers [22, 23]. This may occur due to a higher 
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sensitivity of BRCA2-mutated tumors to DNA damaging chemotherapy (as a result 
of decreased ability to repair DNA following treatment).  
Mathematical simulations combined with genome sequencing data have 
shown that increased levels of passenger mutations (generally considered 
innocuous with respect to direct impact on tumor cell survival)  can actually be 
deleterious to tumor viability during therapy, and that treatments which either 
increase mutational load or increase the impact of mutations already present in 
cells can lead to tumor regression. [24]. A sufficiently high number of passenger 
mutations may contribute to chromosome instability (which can negatively impact 
cell replication and viability), as well as increased immune recognition of tumor 
cells (due to higher production of immunostimulatory neo-antigens) [25]. In 
addition, analysis of The Cancer Genome Atlas (TCGA) data on the basis of high 
versus low mutation load and survival, has shown that patients with tumors that 
exhibit a high level of mutation have better overall and progression-free survival 
compared to patients with tumors that harbour fewer mutations [26].  
Therefore, vulnerability due to high mutational load and an inability to 
counteract the effects of DNA damaging anti-cancer treatment are characteristics 
of tumor cells with reduced or non-functional DNA repair pathways. Actively 
inhibiting DNA repair modulators is a promising therapeutic avenue to recapitulate 
these traits in all tumor cells, regardless of baseline DNA repair proficiency.  
In other words, inhibiting DNA repair in tumor cells may sensitize (decrease 
the innate resistance) to specific types of DNA-damaging therapy and render 
cancer cells more responsive to the action of commonly used drugs. It is possible 
this type of approach may also be cancer cell specific, by virtue of the highly de-
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regulated genomic landscape which renders tumor cells closer to the proverbial 
“edge of viability” [27] (Figure 2). This concept is based on the premise that cells 
must maintain a minimum level of genomic fidelity to survive (the edge of viability). 
Mutations and chromosomal aberrations present in tumor cells decrease the 
baseline level of genome fidelity and thus render cancer cells closer to the 
theoretical edge, past which survival is not possible. Non-cancerous cells, which 
are further away from the edge of survival due to a low mutation load, also exhibit 
rigidly controlled DNA replication and repair mechanisms that ensure that they do 
not progress through the cell cycle when damage occurs.  A comparatively high 
proportion of tumor cells exhibit compromised cell cycle and DNA replication 
control, which may render them vulnerable to therapeutic attack that increases 
mutation load and/or DNA damage, pushing them over the edge of viability [27].   
In addition, actively inhibiting DNA repair in cancer cells may reduce 
acquired resistance by preventing therapy-mediated selection of clones that exhibit 
high DNA repair ability within a heterogeneous population of cells. In a polyclonal 
tumor environment, subpopulations with more proficient repair mechanisms may 
survive treatment. Actively inhibiting DNA repair will help to prevent selection 
based on DNA repair ability, because these processes will be (in theory) impaired 
in all tumor cells (irrespective of baseline repair proficiency).  
 
1.4 Antisense molecules as therapeutic agents 
Two major classes of antisense molecules being explored for therapeutic 
use are short interfering RNAs (siRNAs) (20-25 mer RNA duplexes) and antisense  
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Figure 2 – Mutational load and “edge of viability” in tumour cells. In this 
theoretical graph, cancer cells are thought to be closer to the “edge of viability” due 
to a higher than normal mutational load. Thus, treatments that increase DNA damage 
and mutation may preferentially affect cancer cells, which usually exhibit 
compromised cell cycle control and/or apoptotic pathways. Normal cells, which have 
a lower mutational load and exhibit tightly controlled DNA replication and repair 
mechanisms, are further from that edge and will not accumulate mutations or genome 
abnormalities as readily. This phenomenon is supported by evidence showing that 
patients with tumours that exhibit a higher mutational load and/or DNA repair defects, 
respond more favourably to therapy.  
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oligodeoxynucleotides (ASOs) (20-25 mer single-stranded DNA molecules) [28]. 
siRNAs bind to complementary RNA within the cell and induce Argonaute 2-
mediated degradation of the target transcript via the RNA-induced silencing 
complex (RISC) [29]. Eukaryotic cells utilize RISC for post-transcriptional gene 
regulation (via endogenous RNA-interference molecules such as microRNAs 
(miRs)), and exogenous siRNAs exploit these naturally occurring pathways for both 
experimental and therapeutic applications.  ASOs, unlike siRNAs, mediate target 
RNA destruction via the RNAse H pathway, which normally degrades RNA-based 
DNA primers to ensure efficient DNA synthesis [30]. ASOs for therapeutic or 
experimental use exploit this naturally occurring phenomenon by forming DNA-
RNA hetero-duplexes with target RNA and inducing their degradation via RNAse 
H [31].  
The use of antisense-based therapeutic agents holds significant promise 
because it can target pathways considered “undruggable” by conventional 
approaches (e.g., small molecule inhibitors and therapeutic antibodies). Antisense 
molecules can induce degradation of target mRNA via complementary base pairing 
and, in theory, any RNA product can be silenced by antisense approaches [32]. 
Another important advantage of antisense based drugs is high specificity 
and the relative lack of toxicity. Small molecule inhibitors, such as those targeting 
enzymatic active sites, can often have significant off-target effects due to agent 
promiscuity. However, antisense molecules are sequence specific and can be 
engineered to limit toxicity or off-target mRNA degradation by specific chemical 
modification. For instance, the addition of a 2’-OMe group has been shown to 
decrease off-target transcript degradation by 80% [33]. Oligodeoxynucleotides also 
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have the potential to stimulate pattern recognition receptors (PRRs) (such as Toll-
Like Receptors (TLRs) and cytoplasmic receptors like PKR or RIG-I) and thus 
induce an innate immune response (e.g., type I interferon). The occurrence of this 
can be limited by replacing immunostimulatory bases such as guanosine and 
uridine, with relatively non-stimulatory bases such as adenosine [33].  
One of the barriers to successful antisense clinical application has been the 
lack of an efficient in vivo delivery system. However, the chemical characteristics 
of ASOs (which, as single-stranded DNA molecules, lack the labile, alkali-sensitive 
hydroxyl group on carbon 2 of the pentose sugar present in antisense RNA 
molecules and are of lower molecular weight than double-stranded antisense RNA) 
have greatly increased uptake and stability in vivo without the need for a delivery 
vehicle [34]. In addition, different types of liposomal delivery vehicles have been 
designed for siRNA use to protect siRNA from cleavage and to enhance their 
delivery into target cells [32, 35], and some of these are being tested clinically [36].  
As a result, both classes of antisense molecules described herein have been 
utilized successfully in animal models in vivo, and have also made the transition to 
various stages of human application (e.g., clinical trials and FDA approval). 
Mipomersen is one FDA approved ASO drug which targets apolipoprotein 
B and is used for the treatment of familial hypercholesterolemia. It is administered 
on a weekly basis without a delivery vehicle [37, 38]. In the cancer treatment 
sphere, a number of ASO-based drugs developed by different companies are at 
varying stages in the clinical pipeline [28, 29]. Custirsen (OGX-011) is an ASO 
agent that has been investigated in Phase I and II clinical trials for use in prostate 
cancer, and has demonstrated survival and palliative benefit [39, 40]. Phase III 
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trials of this drug are currently ongoing for both castration-resistant prostate cancer 
(second line) as well as advanced or metastatic non-small cell lung cancer 
(NSCLC) [41].     
siRNA molecules have been delivered in vivo to downregulate a multitude 
of targets in tumor xenografts [42, 43] and also in clinical trials [35, 44, 45]. In one 
trial, siRNA was used to downregulate VEGF and KSP in patients with liver 
metastases, and showed anti-tumor activity while inducing minimal side-effects 
[36]. These studies highlight the promise of antisense based drugs and show that 
the true potential of this technology is still untapped clinically.  
 
1.5 Overcoming innate resistance through complementary lethality – sensitizing 
cancer cells to therapy  
 The effect of DNA-damaging therapy can be attenuated by functioning DNA 
repair pathways in tumor cells [46]. Thus, intact DNA repair pathways are a source 
of intrinsic (or innate) resistance to common types of anti-cancer therapy and 
inhibition of DNA repair mediators is an avenue to sensitize cancer cells to 
treatment. I termed this concept “complementary lethality” and defined it as the 
enhancement of therapeutic efficacy by inhibition of factors important for cellular 
resistance to the action of that specific therapy (Figure 3) [47].   
 BRCA2 is intimately involved in DNA repair and replication in human cells. 
It functions as a scaffold by displacing replication protein A (RPA) on the single-
stranded DNA tails which flank sites of double-stranded breaks  (DSBs), and 
promotes RAD51 loading onto DNA to initiate the process of HRR [48]. 
Furthermore, BRCA2 prevents the degradation of stalled replication forks by  
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Figure 3 – Complementary lethality. Factor X is involved in the amelioration of Drug 
X-induced effects in the cell. For instance, Factor X can be a DNA repair protein and 
Drug X may be inducing DNA DSBs. This limits the efficacy of the drug because the 
function of Factor X is to repair the damage that Drug X promotes. Inhibiting Factor X 
will eliminate Factor X-mediated resistance to Drug X in a complementary manner.   
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stabilizing RAD51 filament formation via its C-terminal domain, in a process 
separate from the functions of BRCA2 in HRR [49]. In addition, BRCA2 is active 
during the spindle assembly checkpoint (SAC) and promotes the acetylation of 
BuBR1 (a crucial mediator of the SAC) by recruiting the PCAF acetyltransferase 
[50]. As a result, BRCA2 represents a source of innate resistance to a variety of 
chemotherapeutic drugs, particularly DNA alkylators and platinators which induce 
damage that lead to DSBs [51]. This role, combined with the more favourable 
prognosis of patients with BRCA2 mutated tumors [22, 23], render BRCA2 an 
intriguing target for direct therapeutic intervention in combination with other specific 
treatments. Such a strategy contrasts with simply identifying the individuals with 
BRCA2-mutated cancers and tailoring treatment accordingly [52], which though 
potentially valuable, has the potential to aid only a small proportion of patients.    
 The cytotoxic agent cisplatin is commonly used to treat a variety of solid 
human tumors, including lung and head and neck cancers [16, 53]. Cisplatin 
induces cytotoxicity by causing DSBs in cellular DNA, leading to replication 
collapse and apoptosis [54]. Resistance to cisplatin develops with high frequency 
via several mechanisms [51, 55], and in most cases treatment fails to cure patients 
of disease. Given the role of BRCA2 in DSB repair through HRR, inhibiting BRCA2 
in the context of cisplatin treatment may be a method to induce complementary 
lethality and increase tumor cell sensitivity (decrease innate tumor cell resistance) 
to cisplatin. 
 In addition, due to the high degree of heterogeneity present in most solid 
tumors and the correspondingly high probability of resistance to treatment, it may 
be favourable to induce complementary lethality to another class of drugs by 
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targeting a separate pathway simultaneously. Theoretically, this should decrease 
the probability of a pre-existing resistant subpopulation being present at the start 
of treatment, which is favourable in terms of patient outcome and preventing 
therapeutic failure [12].    
One potential candidate for this type of combination treatment is thymidylate 
synthase (TS). TS is responsible for de novo synthesis of cellular thymidylate 
(dTMP) and is the target of several anti-cancer drugs, including fluoropyrimidines 
and folate analogs (e.g., 5-FU, 5-FUdr, pemetrexed, etc.) [56]. Inhibition of TS or 
the TS pathway results in decreased pools of dTMP available for DNA synthesis, 
which negatively impacts tumor cell replication and growth. However, similar to the 
case of cisplatin, resistance to this class of drugs is common, and TS has been 
well-studied in our laboratory as a potential target to prevent drug resistance [57]. 
Previous studies have shown that downregulation of TS sensitizes tumor cells to 
TS-targeting drugs and can render resistant cells sensitive to treatment [56, 58, 
59]. Therefore, both BRCA2 and TS appear to function as innate sources of 
resistance to two different types of chemotherapy, which target DNA replication 
and repair from separate angles. It is possible, therefore, that combined inhibition 
of both BRCA2 and TS may be an avenue to increase tumor cell susceptibility to 
two distinct drug classes at the same time (Figure 4A&B).     
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Figure 4 – Combined inhibition of BRCA2 and TS: combined complementary 
lethality. (A) DNA damaging drugs such as cisplatin induce DSBs in cellular DNA, while 
TS-targeting agents inhibit the function of TS; they are involved in largely separate 
pathways inside the cell. However, the effectiveness of these drugs can be decreased, 
and the cell can be rescued from their action if it expresses functional BRCA2 and 
maintains residual TS activity (innate sources of resistance to these drugs). (B) When 
DNA damaging drugs and TS-targeting drugs are administered in combination with 
antisense molecules targeting both resistance factors (BRCA2 and TS), the cell will be 
more susceptible to drug induced effects. This type of “combined complementary 
lethality” which targets innate sources of resistance, may also be a way to prevent the 
development of acquired resistance in heterogeneous tumor cell populations, by 
decreasing the likelihood of cancer cell survival following treatment.  
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Such a strategy may more effectively eliminate cancer cells by overcoming 
innate resistance, and decreasing the probability of acquired resistance appearing 
in the population: a tumor cell would have to develop counter measures not only to 
two separate classes of drugs, but also to sensitization to those drugs. For 
instance, drug efflux pumps decrease the concentration of drug in the cytoplasm, 
but a sensitized cell may still be negatively affected despite the lower drug 
concentration (relative to an un-sensitized cell).  
Our group has previously developed and tested a TS-targeting ASO in pre-
clinical in vitro and in vivo models   [56, 58, 60]. A significant portion of this thesis 
is devoted to testing a novel BRCA2-targeting ASO that I aim to use in conjunction 
with chemotherapeutic drugs such as cisplatin, as well as combining it with our TS-
targeting ASO to create multi-drug sensitive tumor cells.     
 
1.6 Preventing and overcoming acquired resistance – reciprocal positive 
selection for weakness 
 Anti-cancer treatment acts as a powerful positive selection tool which 
destroys susceptible cells and enriches the population of cells resistant to a 
particular therapy. In a clinical setting, this can lead to an increase in progression 
free survival, but rarely an appreciable difference in overall survival since the 
tumors almost inevitably recur as a result of acquired resistance [18, 61].  
 As described above, one method that may prevent or delay the onset of 
therapeutic failure is to induce complementary lethality by inhibiting a target like 
BRCA2 or TS to sensitize tumor cells to the specific action of a drug or combination 
18 
 
of drugs. Such a strategy attempts to increase the likelihood that drug treatment 
will affect the largest proportion of tumor cells, and decrease the mathematical 
probability of pre-existing resistance based on tumor size and mutation rate.  
 However, a second method to minimize the probability of resistance and 
increase the duration of therapeutic response is to employ a treatment regimen 
that selects for weakness in the tumor cell population instead of fitness. This can 
seem contrary to the principles of Darwinian evolutionary thought, but I hypothesize 
it can be achieved using a carefully orchestrated combination therapy regimen 
involving simultaneous inhibition of BRCA2 and PARP1. 
 PARP1 is an enzyme involved in a variety of cellular processes, including 
DNA repair and replication. More specifically, PARP1 regulates single strand break 
(SSB) DNA repair which is essential for normal DNA replication [62]. If SSBs are 
left unresolved they can cause replication fork collapse, which results in DSBs that 
must be repaired by HRR or the error prone non-homologous end joining (NHEJ) 
pathway [63]. In addition, PARP1 is directly involved in the maintenance of stalled 
replication forks by preventing MRE11-mediated degradation of DNA. When a 
replication fork is stalled due to base damage or other obstacles that hinder the 
progression of DNA polymerase, MRE11 acts as an endonuclease which degrades 
the DNA, causing fork collapse and replication failure. PARP-1 prevents this 
occurrence and maintains replication fork integrity, providing the time necessary 
for damage to be repaired [64].  
 Given the role of PARP1 in DNA repair and replication, the PARP1 inhibitor 
olaparib is synthetically and selectively lethal in cells with HRR defects, but does 
not affect HRR-proficient cells [65-67]. In the absence of functional HRR, the cell 
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is unable to repair the DSBs that result from PARP-1 inhibition (via unresolved 
SSBs), which results in lethal DNA damage. This ability to spare non-cancerous, 
HRR-proficient cells was the basis for much of the enthusiasm surrounding PARP1 
inhibition and spawned a large effort by the biotechnology industry to identify, test, 
and market a gamut of PARP1-inhibiting drugs [68]. After several clinical trials with 
mixed results and an FDA rejection for accelerated drug status, Olaparib was 
approved by the FDA for use in advanced ovarian cancer patients with validated 
BRCA gene mutations [69]. Another PARP1 inhibitor called Veliparib is currently 
undergoing a Phase III clinical trial as a first-line therapy in combination with 
chemotherapy for BRCA-mutation-positive breast cancer [70].   
However, the same characteristics and circumstances that render PARP1 
inhibition so attractive in oncology (selective killing of tumor cells with HRR defects) 
is also part of what ultimately nullifies its effectiveness. For one, this limits the 
applicability and usefulness of PARP1 inhibitors to the treatment of HRR-deficient 
tumor cells, which represents only a subset of all cancer patients [26, 71]. 
Furthermore, selective killing in a heterogeneous tumor population may rapidly 
lead to the outgrowth of HRR-proficient, resistant clones and therapy failure. 
At least five separate PARP1 inhibitor resistance mechanisms have already 
been identified in in vitro experiments and in clinical studies, including upregulation 
of drug efflux pumps that decrease drug concentration inside the cell, and 53BP1 
mutations that reactivate HRR pathway functionality in BRCA1 deficient cells [72-
74]. However, the most striking resistance mechanism is the reported reversion of 
BRCA2-mutated tumors to functional BRCA2 following olaparib treatment [75]. The 
implications of this finding are twofold: 1) BRCA2 mutation status (and by extension 
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HRR-proficiency) is heterogeneous, even in a tumor population primarily 
composed of BRCA2 mutated cells and; 2) The selection pressure for HRR 
proficiency is so great during PARP1 inhibitor treatment, that tumor cells with 
functional HRR have a distinct survival advantage and will eventually overtake the 
HRR-deficient population. 
PARP1 inhibitor resistance displays the need for a new combinatorial 
approach to their application in the clinic. Given the unique relationship between 
PARP1 and HRR status, it is inevitable that PARP1 inhibition alone will simply 
select for a small group of subclones in the population that are proficient for HRR. 
I hypothesize, therefore, that resistance based on HRR function can be forestalled 
or even eliminated by combining inhibition of PARP1 and BRCA2.  
In a tumor population with heterogeneous HRR proficiency, olaparib 
treatment will eliminate the HRR-deficient cells and select for the HRR-proficient 
clones. BRCA2 inhibition, on the other hand, will affect cells with intact HRR and 
select for HRR-deficient cells. Therefore, in this scenario, PARP1 inhibition selects 
for cells that are susceptible to BRCA2 inhibition, and BRCA2 inhibition selects for 
cells that are sensitive to PARP1 inhibition. I termed this concept “reciprocal 
positive selection for weakness”, since each treatment selects for cells which will 
be sensitive (weak) to the other treatment in a reciprocal manner. I believe this may 
be a mechanism to prevent or delay the development of acquired resistance in a 
heterogeneous tumor cell population, by forestalling the enrichment of a particular 
group of subclonal variants with pre-existing resistance to treatment (Figure 5).    
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Figure 5 – Reciprocal positive selection for weakness. In a population 
heterogeneous for HRR-proficiency, BRCA2 inhibition will impair the growth of HRR-
proficient cells and select for HRR-deficient cells. PARP-1 inhibition will accomplish 
the reciprocal of that by impairing the growth of HRR-deficient cells while selecting for 
HRR-proficient cells. Therefore, each treatment selects for cells that are susceptible 
to the other treatment. When BRCA2 and PARP1 inhibition is combined, both HRR-
proficient and HRR-deficient cells are affected, nullifying selection based on HRR-
proficiency. 
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1.7 Hypothesis 
Inhibiting DNA repair pathways will overcome innate drug resistance and prevent 
acquired drug resistance in human cancer cell populations. 
 
1.8 Objectives: 
1) To investigate whether BRCA2 siRNA can sensitize cancer cells (i.e., A549 
and HeLa) to specific DNA-damaging chemotherapeutic drugs (i.e., cisplatin 
and melphalan) related to BRCA2 function.  
2) To determine whether combined BRCA2 siRNA and TS siRNA treatment 
can render cancer cells (i.e., A549 and HeLa) sensitive to multi-drug 
treatment (i.e., cisplatin or melphalan and 5-FUdR or pemetrexed). 
3) To develop and test a BRCA2 targeting ASO and determine effects on tumor 
cell proliferation (via cell counting and colony formation assays), metastasis 
(via in vivo chick cam assays) and metabolic response (respiration and 
acidification) when combined with cisplatin treatment.  
4) To determine whether BRCA2 ASO treatment can overcome innate 
resistance to the PARP1 inhibitor olaparib in a variety of cancer cell lines 
(i.e., A549, H2052, SKOV-3, CaOV-3, MDA-MB-231) 
5) To investigate whether combined BRCA2 and PARP1 inhibition can prevent 
therapeutic resistance in a tumor cell population heterogeneous for HRR-
proficiency, using a 3:1 co-culture model of HRR-proficient and HRR-
deficient cells (SKOV-3shcontrol and SKOV-3shBRCA2) to monitor long term 
response to treatment.  
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6) To determine whether combined BRCA2 siRNA and olaparib treatment can 
decrease ovarian tumor growth in vivo (number of nodules and total tumor 
weight) using an orthotopic model of intraperitoneal SKOV3-1P1 cell 
injection, and whether the magnitude of tumor growth suppression is higher 
than with either treatment alone.  
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Chapter 2. Materials and Methods: 
 
2.1.0 - Cell lines 
 Human lung (A549), cervical (HeLa), mesothelioma (211H & H2052), 
ovarian (SKOV-3 & CaOV3), breast (MCF-7 & MDA-MB-231) and BRCA2-mutated 
pancreatic (CAPAN-1) cancer cells, as well as non-tumorigenic kidney (HK-2) and 
colon (CCD-841) cells were obtained from ATCC (Manassas, Virginia, USA) and 
maintained in AMEM, DMEM, or Iscove's medium (Wisent, St. Bruno, Quebec, 
Canada) supplemented with 10 or 20% fetal bovine serum (FBS) (GIBCO - 
ThermoFisher Scientific, Waltham, MA, USA), or Keratinocyte Serum Free medium 
supplemented with bovine pituitary extract and human recombinant epidermal 
growth factor (GIBCO – ThermoFisher Scientific) under standard conditions (37° 
C in a humidified 5% CO2 atmosphere). Parental human head and neck squamous 
carcinoma HN-5a cells and cisplatin-resistant HN-5a/carbo15a cells [76] were 
maintained in AMEM medium with 10% FBS under standard conditions. Cell 
culture plastic-ware was obtained from Invitrogen, Fisher Scientific (Unionville, 
Ontario), and VWR International (Mississauga, Ontario).  
 
2.1.1 - siRNA transfection 
siRNA transfection was performed according to the following protocol: the 
concentrations of siRNAs targeting human BRCA2 (OnTarget Plus BRCA2 siRNA 
#4 or OnTarget Plus SMARTPool BRCA2 [Dharmacon RNAi Technologies, 
Lafayette, CO, USA]) and human TS (OnTarget Plus TS siRNA #2; [Dharmacon]) 
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that reduced target mRNAs by approximately 70% at 24 h post-transfection were 
determined (10 nM for BRCA2 siRNA, and 2.5 nM for TS siRNA). To apply equal 
amounts of siRNA to A549 and HeLa cells in studies where BRCA2 and TS were 
knocked down individually or collectively, control non-targeting siRNA (Dharmacon 
control siRNA #2 or control SMARTPool) was added to BRCA2 siRNA or TS siRNA 
so that the total siRNA concentration applied in every case was 12.5 nM. BRCA2 
siRNA (10 nM plus 2.5 nM control non-targeting siRNA), TS siRNA (2.5 nM plus 
10 nM control non-targeting siRNA), for BRCA2 siRNA plus TS siRNA (10 nM plus 
2.5 nM, respectively) were diluted in serum-free AMEM and incubated with diluted 
Lipofectamine 2000 (LFA2K, Invitrogen – ThermoFisher Scientific) for 20 min. The 
siRNA:LFA2K  mix was then added to cells seeded, in triplicate, at a density of 2.0 
x 105 cells in  25 cm2 flasks 24 hours prior to transfection. Medium was exchanged 
for fresh AMEM plus 10% FBS 4 hours post-transfection and the effects of siRNA 
treatments on target mRNA levels and sensitivity to cytotoxic drugs were assessed 
as described below.  
 
2.1.2 - Antisense oligonucleotide (ASO) transfection 
 Oligonucleotide transfection was performed according to the same protocol 
as siRNA transfection (above), with some modifications [47]: BRCA2 ASO or 
control ASO were diluted in serum-free medium and incubated with Lipofectamine 
2000 (Invitrogen - ThermoFisher Scientific) for 20 min, then added to cells to a final 
concentration of 20 nM. After 4 hours, transfection medium was replaced or cells 
were harvested for subsequent treatment as described.   
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2.1.3 – mRNA quantification 
Twenty-four hours post-transfection of siRNA or ASO, total cellular RNA 
was isolated from cells using Trizol® regent (Ambion - ThermoFisher Scientific) 
according to manufacturer’s instructions and reverse-transcribed to generate 
cDNA using M-MLV RT enzyme (Invitrogen - ThermoFisher Scientific). cDNA (1 
μg) was used in conjunction with BRCA2, TS, and 18S or GAPDH RNA qPCR 
probe and primers and Taqman master mix (Applied Biosystems – ThermoFisher 
Scientific) to generate fluorescently labelled target cDNA. Quantification of cDNA 
to infer levels of TS and BRCA2 mRNAs and 18S or GAPDH RNA was performed 
using an Applied Biosystems ViiA 7 Real-time PCR System (ThermoFisher 
Scientific). TS and BRCA2 mRNA levels were determined relative to cellular 18S 
or GAPDH RNA levels. 
 
2.1.4 - Protein immunoblot 
 BRCA2 immunoblotting was performed according to the following protocol: 
cells were transfected with ASO and cell lysates were collected 72 hour post-
transfection. Following a Bradford assay, total cellular protein (40 μg per well) was 
loaded on a 4-15% gradient gel (Bio-Rad, Hercules, California, USA) and 
electrophoresed (1.5 h, 100 V), then transferred to PVDF membrane using a 
BioRad Turbo Transfer Pack (Bio-Rad). The membrane was blocked with TBS-T 
+ 5% BSA for 1 hour and then incubated with BRCA2 MAb (1:500, 16 hours) (Cell 
Signaling #9012S) and actin MAb (1:1000, 1 h) (Sigma-Aldrich Co., St. Louis, MO, 
USA) 
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2.1.5 - Cell cycle analysis 
Cells were transfected with siRNA as described previously. Forty-eight and 
72 hours post transfection they were harvested, washed with PBS, and fixed with 
70% ethanol for at least 2 hours. Cells were washed with PBS and re-suspended 
in 1 ml of a propridium iodide (20µg/ml) (Sigma Aldrich) and 0.1% Triton X-100 
(BDH Chemicals, Toronto, ON Canada) staining solution with RNAse A (Bioshop 
Canada, Inc., Burlington, ON) for 15 minutes at 37⁰C. Cell cycle enumeration was 
performed using a BD FACSCalibur flow cytometer (BD Biosciences, Mississauga, 
ON, Canada) and analyzed using Flow Jo software (Tree Star, Inc., Ashland, OR, 
USA).  
 
2.1.6 - cBioPortal Analysis of TCGA data 
 The cBioPortal website client (http://www.cbioportal.org/public-portal/) was 
utilized to analyze the survival differences in patients with wild type or mutated 
BRCA2 or BRCA1, in both ovarian and endometrial cancer. The analysis was 
performed using the Ovarian Serous Cystadenocarcinoma (Cancer Genome Atlas 
Research Network, 2011) dataset and the Uterine Corpus Endometroid Carcinoma 
[77] dataset. 
 
2.1.7 - Cell proliferation following drug treatment 
 Cells were trypsinized, counted, and re-plated in triplicate at a density of 
2.0-5.0x104 cells per well in a six well plate 24 h post transfection. Cytotoxic drugs 
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(e.g., cisplatin [Sigma Aldrich], melphalan [Sigma Aldrich], 5-FUdr [Sigma-Aldrich], 
pemetrexed [Sigma Aldrich], olaparib [Selleckchem, Boston, USA]) were added in 
triplicate wells for each drug concentration. Cells were trypsinized 76 h after 
addition of drug and counted (twice per sample) using a Coulter Z-1 Particle 
Counter (Beckman-Coulter, Mississauga, ON). Relative proliferation was 
calculated using the starting cell number at seeding, and normalized to the no drug 
ASO treatment condition (e.g., control ASO + drug treatment was normalized to 
control ASO alone).   
 
2.1.8 - Colony formation assay 
 Forty-eight hours post transfection the cells were exposed to different 
concentrations of drug for a total of 6 hours. The cells were collected and plated in 
triplicate at a density of 500 cells per well in a 6 well dish. In the case of irradiation 
treatment, cells were harvested immediately post treatment and plated at a density 
of 500 cells per well in a 6 well dish. Colonies were fixed with a Protocol® Hema-
3 kit (ThermoFisher Scientific) 7-10 days later and counted.  
 
2.1.9 - Chicken chorioallantoic membrane (CAM) metastasis assay 
 Forty-eight hours post transfection cells were exposed to 6 µM of cisplatin 
for 6 hours. The cells were harvested, washed three times, and adjusted to a final 
concentration of 1.0x106 cells per ml in PBS. 1.0x105 cells (100 µl) were injected 
into the venous circulation of 9 day old chicken embryos. Seven to 9 days post 
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injection the metastatic foci were counted using an Axio Zoom V16 (Carl Zeiss AG, 
Germany) microscope at 20x magnification [78].  
 
2.2.0 - Bionas Discovery metabolic measurement 
 Four hours post-transfection cells were collected and seeded onto Bionas 
biosensor chips (Bionas GmbH, Rostock, Germany) at a density of 180,000 cells 
per chip. The medium was changed to AMEM+0.2% FBS and the biosensor chips 
were loaded into the Bionas system (Bionas GmbH) 24 hours later. Using a 4µl/min 
flow rate, the cells were exposed to AMEM+0.2% medium for 6 hours and then 6 
µM cisplatin for 24 hours. The cells were exposed to medium for 48 hours, at which 
point the cells were lysed with 0.1% Triton-X to determine baseline readings [78].  
 
2.2.1 - Glucose uptake assay 
 Twenty-four hours post-transfection cells were treated with 6µM of cisplatin. 
Cells were washed with PBS and then incubated with glucose free DMEM (GIBCO) 
+ 10% FBS for 20 mins, 48 h post drug treatment. The cells were incubated in 
glucose free DMEM+10% FBS+29µM 2-NBD fluorescent glucose (Molecular 
Probes, ThermoFisher Scientific) for 1 h. Cells were collected, washed with PBS, 
and glucose uptake was enumerated using a FACSCalibur2 flow cytometer (BD 
Biosciences, Franklin Lakes, NJ, USA). 
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2.2.2 - Mitotracker assay 
 Twenty-four hours post-transfection cells were treated with 6µM of cisplatin. 
To enumerate the frequency of cells with functional mitochondria, cells were 
harvested and stained with 75nM MitoTracker Red CMXROS (ThermoFisher 
Scientific) [79] according to manufacturer's instructions, 48 hours post drug 
treatment. MitoTracker staining was enumerated using flow cytometry and 
expressed as mean fluorescence intensity (geometric mean). 
 
2.2.3 - AlamarBlue assay for cell proliferation  
 Cells were transfected with ASO as described and re-plated in 96 well plates 
(7.5 X 103 cells per well). Twenty-four hours post transfection cells were treated 
with different concentrations of cisplatin, melphalan, 5-FUdR, or pemetrexed 
(Sigma Aldrich, Co.). Seventy-two hours later medium was removed and a 1:12 
dilution of AlamarBlue (ThermoFisher Scientific) was added for 3 hours. Following 
incubation, the turnover of AlamarBlue reagent was quantified using a Victor2 plate 
reader (Wallac, Perkin-Elmer, USA).   
 
2.2.4 - Rad51 focus formation assay to examine BRCA2 function  
 Cells were transfected with ASO as described previously, except that they 
were grown on microscope slide cover slips in 12 well plates prior to transfection. 
Cells were treated with cisplatin (6 µM, 6 hours) starting 48 hours post-transfection, 
washed with PBS and fixed (4% paraformaldehyde, 30 min), permeabilized (TBS 
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+ 0.3% Triton X-100, 10 min), and blocked (TBS + 3% BSA, 3% goat serum, 1 h). 
Anti-Rad51 MAb (Calbiochem - EMD Millipore, Germany, 1:500) in blocking 
solution was added and incubated at 4° C for 16 h. Cells were washed in TBS and 
incubated with secondary antibody (Cell Signaling,1 h, 25o C), washed again, then 
stained and mounted with DAPI SlowFade Gold anti-fade reagent (Molecular 
Probes, ThermoFisher Scientific) [80]. 
 
2.2.5 - Generation of cells stably expressing shBRCA2 and shControl 
SKOV-3 cells (ATCC) were transfected with linearized plasmids expressing 
the shControl and the 4 shBRCA2 constructs (Cat. No. 336312 Qiagen) using 
Lipofectamine 2000 (Invitrogen) according to manufacturer’s instruction. Seventy-
two hours post transfection, the cells were treated with hygromycin (Sigma Aldrich) 
for seven days. Over 40 individual colonies were isolated using glass isolation rings 
and then expanded. Sensitivity to olaparib was tested using cell counting 
proliferation assays as described above. 
 
2.2.6 - Metaphase spread preparation and chromosome counting 
Four hours post transfection, cells were collected and plated on microwell 
containing glass slides. Drug treatment commenced 24 hours post transfection and 
the cells were allowed to grow for a further 24 hours. Colcemid (Sigma Aldrich) 
was added to the medium for the last 2 hours of culture. The cells were washed 
with PBS and then treated with pre-warmed (37°C) KCL (75 mM) for 20 minutes. 
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Cold (4°C) fixative (3:1 methanol:acetic acid solution) was added to the cells for 2 
minutes. The fixative solution was then replaced with fresh solution and incubated 
for a further 20 minutes. The fixative solution was replaced a final time for another 
20 minutes and the slide was allowed to air-dry at room temperature. The slides 
were then mounted with DAPI or used for subsequent FISH. DAPI mounted slides 
were used to determine chromosome number using an inverted fluorescent 
microscope (Olympus, Tokyo, Japan).  
 
2.2.7 - Fluorescence in situ hybridization (FISH) for whole chromosomes 
Following metaphase preparation, the slides were washed in 2X SSC (pH 
7.0) for 2 minutes at 73°C. The slides were transferred into a 0.005% pepsin 
solution for 10 minutes at 37°C and then washed with PBS for 5 minutes at room 
temperature. The slides were fixed in 1% formaldehyde for 5 minutes at room 
temperature and then washed with PBS. The slides were sequentially dehydrated 
by immersion in 70%, 85% and 100% ethanol. Diluted FISH probes (Empire 
Genomics, Buffalo, NY, USA) were applied to the slide, covered with glass 
coverslips and sealed with rubber cement. The probes and chromosomal DNA 
were co-denatured on a hot plate at 68°C for 5 minutes. Hybridization was 
performed at 43°C in a humidified chamber for 4 hours. Following hybridization, 
the slides were washed with 2X SSC +0.1% Igepal (Sigma Aldrich) at room 
temperature to remove the cover slips and rubber cement. The slides were washed 
at 65°C with 0.4X SSC + 0.3% Igepal for five minutes, rinsed briefly with ddH20 
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and then air dried. The slides were mounted with DAPI mounting medium and 
visualized using an inverted fluorescent microscope.   
 
2.2.8 - In vivo tumor model 
Female athymic nude mice were purchased from the National Cancer 
Institute (Frederick, MD) and all mouse studies were approved and supervised by 
the MD Anderson Cancer Center Institutional Animal Care and Use Committee. All 
animals used were between 8 and 12 weeks of age at the time of injection. To 
establish the tumors, SKOV3ip1 ovarian cancer cells (1.0 x 106) were trypsinized 
and suspended in 200 μl of Hanks balanced salt solution (HBSS; Gibco) and 
injected into the intraperitoneal cavity (i.p.) of mice on day 1. Seven days after cell 
injection, mice were randomly divided into 4 groups: 1) Control siRNA/DOPC or 2) 
BRCA2 siRNA/DOPC or 3) Control siRNA/DOPC + olaparib or 4) BRCA2 
siRNA/DOPC + olaparib (n=10 mice per group). Treatment began by injecting 
siRNA/DOPC nanoparticles twice weekly (150 µg/kg body weight) and olaparib (5 
mg/kg body weight; 5 days a week) through i.p. injection. Mice were monitored 
daily for adverse effects of therapy and were sacrificed when they became 
moribund (6-7 weeks after cell injection) [81]. At the time of sacrifice, mouse and 
tumor weight was recorded. Tumor tissue was harvested and either fixed in 
formalin for paraffin embedding, or frozen in optimum cutting temperature medium 
(OCT; Miles, Inc., Elkhart, IN, USA) to prepare frozen slides, or snap-frozen in 
liquid nitrogen for lysate preparation. The individuals who performed the 
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necropsies, tumor collections, and tissue processing were blinded to the treatment 
group assignments. 
 
2.2.9 - Statistical analysis 
For measures of drug sensitization Student’s t tests were employed to 
compare means between groups and test the a priori null hypothesis that there 
was no difference between specific means. A p-value of less than 0.05 was 
selected a priori as the benchmark for rejection of the null hypothesis. For 
determination of increased variation in chromosome number following treatment, a 
statistical analysis of standard deviation was performed via the Bartlett’s test to 
evaluate the null hypothesis that the standard deviation between groups was the 
same.  
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Chapter 3. Inhibition of BRCA2 and thymidylate synthase creates multidrug 
sensitive tumor cells via the induction of combined “complementary 
lethality” 
 
3.1 Preamble: 
Genomic instability and cellular heterogeneity are among the strongest 
drivers of cancer progression, malignancy, and recurrence [82, 83]. A high 
mutation level and chromosomal instability enhances the rate at which malignant 
characteristics are generated in human cells to produce progressively more 
aggressive tumors [27, 84]. Next-generation sequencing (NGS) technology has 
highlighted the extreme degree of genomic variability and mutation present in 
human malignancies [83, 85, 86]. This underscores one of the reasons human 
cancers are difficult to treat effectively – genomic plasticity and phenotypic 
heterogeneity allow for rapid adaptation and differential response to environmental 
selection pressures [27]. 
However, continuing high mutation frequency and lack of genomic fidelity 
also leads to increased rates of cell death [87]. Consequently, cancer cells may be 
closer to a maximum tolerated threshold of mutation than normal cells and are 
highly dependent for continued survival on cellular molecules that maintain at least 
some integrity of genetic information. This phenomenon has led to the concept of 
tumor cell 'addiction' to some mediators of DNA repair [88]. Therefore, targeting 
factors critical to DNA maintenance may be a useful strategy to promote an 
increase in DNA damage from which cancer cells cannot recover, thus decreasing 
innate resistance to DNA damaging therapy. 
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As mentioned above BRCA2 promotes repair of DSBs [48, 89], and 
mutations in the BRCA2 gene induce a highly penetrant, autosomal dominant 
predisposition to a variety of cancers [20, 90, 91]. However tumors with BRCA2 
mutations respond better to chemotherapy than BRCA2-intact tumors in patients 
with sporadic cancer [23, 92, 93]. Thus, BRCA2 constitutes a source of innate 
resistance to DNA-damaging drugs. TS is the only de novo source of cellular 
thymidylate and is a well-established target of many approved anti-cancer drugs 
including fluoropyrimidines (e.g., 5-FU) and folate analogs (e.g., pemetrexed) [57]. 
My group previously reported that TS antisense oligonucleotides (ASOs) can 
overcome inate resistance to TS-targeting drugs in human cancer cells [58, 59]. 
This led me to formulate and test the concept of ‘complementary lethality’, 
defined as the enhancement of drug efficacy by downregulation of factors 
important for cellular resistance to the action of that specific drug. In other words, I 
propose to potentiate the effectiveness of chemotherapeutic drugs by targeting 
DNA repair mediators, such as BRCA2, which are functionally involved in the 
amelioration of specific types of drug-induced effects (e.g., DSBs produced by 
platinating or alkylating agents).  
I hypothesized that BRCA2 could be downregulated in combination with TS 
to induce complementary lethality to a wider and different spectrum of drugs, thus 
creating multi-drug sensitive tumors. The association of both BRCA2 and TS with 
different aspects of DNA integrity suggests that combined downregulation of both 
targets could lead to enhanced cell death and potentiation of both TS-targeting and 
other drugs that induce or enhance accumulation of DNA damage. 
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In this chapter, I demonstrate that actively targeting DNA repair pathways is 
potentially useful therapeutically and decreases innate resistance to specific 
chemotherapeutic drugs, a phenomenon I labelled complementary lethality. In 
particular, I show that BRCA2 is valuable as a therapeutic target in addition to TS, 
and that combined downregulation of BRCA2 and TS can sensitize cells to a panel 
of chemotherapeutic drugs with different mechanisms of action. I used siRNAs 
targeting TS and BRCA2 to promote sensitization to separate classes of 
chemotherapeutics in the same human tumor population, and induced a state of 
combined complementary lethality resulting in decreased tumor cell proliferation. 
 
3.2. Results: 
3.2.1 – siRNA-mediated knockdown of BRCA2 and TS reduces cancer cell growth 
and affects cell cycle progression  
siRNA-mediated target mRNA downregulation was confirmed by RT-qPCR 
24 hours post transfection. There were no synergistic or inhibitory effects in mRNA 
levels when both targets were downregulated at the same time (Figure 6A). Given 
the potential for baseline DNA damage normally accrued by mammalian cells and 
repaired by complexes in which BRCA2 is important, it was hypothesized that 
BRCA2 siRNA would have an effect on cell growth even in the absence of an 
exogenous damaging agent.  Ninety-six hours post-transfection, A549 cells treated 
with BRCA2 siRNA (10 nM) exhibited a significant decrease in cell number (20% ± 
9%, p=0.036) compared to cells treated with control siRNA (10 nM) (Figure 6B). 
Cells transfected with TS siRNA (2.5 nM) did not appear to be negatively affected 
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by this treatment compared to cells transfected with control, non-targeting siRNA. 
Combination treatment with BRCA2 siRNA (10 nM) and TS siRNA (2.5 nM) 
decreased A549 cell number to a similar level as BRCA2 siRNA alone (29.6% ± 
7.0%, p=0.04 vs control siRNA; no difference vs BRCA2 siRNA) (Figure 6B), 
suggesting that these are separate and non-overlapping pathways. In HeLa cells 
tested under the same conditions, both BRCA2 and TS siRNA, as well as their 
combination, induced decreases in cell number (Figure 6C). 
To assess the possibility that the difference in cell number following siRNA 
treatment was due to cell cycle changes, A549 cells were transfected with BRCA2 
and TS siRNA and then stained with propidium iodide (PI) for cell cycle analysis. 
Forty-eight hours post transfection, BRCA2 siRNA induced a small increase in the 
number of cells in G0/G1 phase (8.15% ± 2.14%, p=0.007), and a concomitant 
decrease in the number of cells in S phase (14.8% ± 3%, p=0.009) compared to 
treatment with non-targeting siRNA (Figure 6D).  
TS siRNA treatment exhibited the opposite effect, with an accumulation in 
S phase (26.7% ± 1.1%, p=0.0002) and a decrease in G0/G1 (32% ± 2.21%, 
p=0.00004). Combined downregulation of both TS and BRCA2 led to a cell cycle 
profile that reflected the opposite contributions of the individual siRNA treatments 
in terms of G0/G1 and S phase frequency which, as a result, yielded cell cycle 
frequencies that were intermediate when compared to control siRNA treatment 
(G0/G1 change: -19.8% ± 4.9%, p=0.005; S change: +13.8% ± 1.9%, p=0.01). 
However, the G2/M phase frequency in BRCA2 and TS siRNA treated cells was 
increased compared to control (10.4% ± 3%, p=0.04) (Figure 6D).  
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Figure 6 – Combined BRCA2 siRNA and TS siRNA inhibits A549 cell proliferation and 
affects cell cycle distribution. A) A549 cells were transfected with control siRNA , TS 
siRNA and/or BRCA2 siRNA. mRNA was isolated 24 hours later. TS mRNA (black bars) 
and BRCA2 mRNA (white bars) levels were measured relative to 18S endogenous control.  
B) Effect of siRNA treatment on A549 cell proliferation, 96 hours post-transfection. C) Effect 
of siRNA treatment on HeLa cell proliferation, 96 hours post-transfection. *Different from 
treatment with control siRNA ( p<0.05). Representative data from one of three independent 
experiments is shown (mean ± SD). D) A549 cells were transfected with control siRNA 
(black bars), TS siRNA (white bars), BRCA2 siRNA (white bars with pattern), or TS siRNA 
plus BRCA2 siRNA (grey bars) and the number of cells in different cell cycle stages 
measured 48 h post transfection. *Different from treatment with control siRNA (p<0.05). 
Representative data from one of two independent experiments is shown (mean ± SD).   
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3.2.2 - BRCA2 siRNA potentiates cisplatin, melphalan, and to a lesser extent 5-
FUdR, but not pemetrexed 
I investigated whether BRCA2 siRNA altered the capacity of A549 cells to 
proliferate after treatment with DNA-damaging chemotherapeutic drugs such as 
cisplatin. Cisplatin binds to DNA and induces inter- and intra-strand crosslinks 
which progress to double stranded breaks (DSBs) and are repaired by homologous 
recombination (HR) [21]. In A549 cells treated with BRCA2 siRNA and cisplatin, 
drug treatment was 43% ± 3% (p=0.0001) more effective when compared to cells 
transfected with non-targeting control siRNA (Figure 7A).  
I determined whether potentiation of cisplatin treatment by BRCA2 siRNA 
was due to the induction of DNA strand crosslinking and subsequent DSBs, by 
using another anti-cancer agent with a related mechanism of action. Melphalan is 
a DNA alkylator but not a platinum based agent and is therefore structurally distinct 
from cisplatin [94]. A549 cells transfected with BRCA2 siRNA 24 hours prior to 
melphalan treatment were 63% ± 0.3% (p=9.5x10-7) more sensitive to melphalan-
mediated growth inhibition than cells treated with control non-targeting siRNA 
(Figure 7B).  
I tested whether siRNA-mediated knockdown of BRCA2 potentiated the 
effects of a folate antimetabolite (pemetrexed) and a fluoropyrimidine (5-FUdR), 
both approved for use in treatment of a broad range of human tumors [95, 96]. 
These drugs are not DNA alkylators and do not share a mechanism of action with 
cisplatin and melphalan. Rather, they inhibit the action of TS and consequently 
starve cells of the thymidylate necessary for DNA replication and repair [57]. Cells  
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Figure 7 – BRCA2 siRNA induces complementary lethality to treatment with 
cisplatin, melphalan and 5-FUdR, but not pemetrexed in A549 cells. A549 cells were 
transfected with control siRNA (black bars) or BRCA2 siRNA (white bars) and treated 
with (A) cisplatin, (B) melphalan, (C) 5-FUdR, or (D) pemetrexed. Effects on cell growth 
were assessed 96 h post transfection, as a percentage of cells treated with control non-
targeting siRNA alone. *Different from treatment with control siRNA alone (p<0.05). 
**Different from treatment with drug plus control siRNA (p<0.05). Representative data 
from one of three independent experiments is shown (mean ± SD).  
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Figure 8 – BRCA2 siRNA induces complementary lethality to treatment with 
cisplatin, melphalan and 5-FUdR, but not pemetrexed in HeLa cells. HeLa cells 
were transfected with control siRNA (black bars) or BRCA2 siRNA (white bars) and 
treated with (A) cisplatin, (B) melphalan, (C) 5-FUdR, or (D) pemetrexed. Effects on cell 
growth were assessed 96 h post transfection, as a percentage of cells treated with 
control non-targeting siRNA alone. *Different from treatment with control siRNA alone 
(p<0.05). **Different from treatment with drug plus control siRNA (p<0.05). 
Representative data from one of two independent experiments is shown (mean ± SD).  
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transfected with BRCA2 siRNA (10 nM) were 31.2% ± 3.1% (p=0.001) more 
sensitive to 5-FUdR than cells transfected with control siRNA  96 hours post 
transfection (Figure 7C). The majority of this effect was driven by the growth 
inhibitory action of the BRCA2 siRNA itself, however a statistically significant 
difference still exists even after normalization for the effect of siRNA on its own. 
BRCA2 siRNA treatment did not sensitize A549 cells to pemetrexed and cell 
numbers were similar to control siRNA transfected cells 96 hours post-transfection 
(Figure 7D). These results were broadly reproducible in HeLa cells tested under 
the same conditions, and BRCA2 inhibition induced complementary lethality to 
cisplatin, melphalan, and to a lesser extent 5-FUdR (Figure 8A-D). 
 
3.2.3 - TS siRNA potentiates 5-FUdR and pemetrexed but not cisplatin or 
melphalan   
A549 cells were transfected with control and/or TS siRNA, and then treated 
with 5-FUdr 24 hours later. As predicted, TS siRNA sensitized cells to 5-FUdR, 
reducing cell proliferation by 55.3% ± 4.9% (p=0.0006) relative to cells treated with 
control siRNA (Figure 9A). In addition, TS siRNA also induced complementary 
lethality to pemetrexed 96 hours post-transfection and decreased cell number by 
56.0% ± 3.5% relative to cells treated with 5-FUdR and control siRNA (p=0.0003) 
(Figure 9B). 
I determined whether TS siRNA sensitized A549 cells to drugs which do not 
target the TS pathway. A549 cells transfected with TS siRNA (2.5 nM) did  
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Figure 9 – TS siRNA induces complementary lethality to 5-FUdR and pemetrexed 
but not cisplatin or melphalan in A549 cells. A549 cells were transfected with control 
siRNA (black bars) or TS siRNA (white bars) and treated with (A) 5-FUdR, (B) 
pemetrexed, (C) cisplatin, or (D) melphalan. Effects on cell growth were assessed 96 h 
post transfection, as a percentages of cells treated with control non-targeting siRNA 
alone. *Different from cells treated with control non-targeting siRNA alone (p<0.05). 
**Different from cells treated with control non-targeting siRNA plus drug. Representative 
data from one of three independent experiments is shown (mean ± SD). 
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Figure 10 – TS siRNA induces complementary lethality to 5-FUdR and pemetrexed 
but not cisplatin or melphalan in HeLa cells. HeLa cells were transfected with control 
siRNA (black bars) or TS siRNA (white bars) and treated with (A) 5-FUdR, (B) 
pemetrexed, (C) cisplatin, or (D) melphalan. Effects on cell growth were assessed 96 h 
post transfection, as a percentages of cells treated with control non-targeting siRNA 
alone. *Different from cells treated with control non-targeting siRNA alone 
(p<0.05).**Different from cells treated with control non-targeting siRNA plus drug. 
Representative data from one of two independent experiments is shown (mean ± SD). 
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not exhibit increased sensitivity to cisplatin (Figure 9C) or melphalan (Figure 9D) 
compared to cells treated with drug and control siRNA. This suggested that TS 
siRNA-mediated potentation of drug efficacy is limited to drugs that target the TS 
pathway and not drugs that induce specific types of DNA damage. These results 
were reproduced in HeLa cells under the same experimental conditions (Figure 
10A-D), and though TS siRNA induced a statistically significant difference in cell 
number following cisplatin and melphalan treatment, this was an additive response 
driven by the action of TS siRNA alone on cell number. After normalization for the 
effect of siRNA alone, there was no statistically significant difference relative to 
control siRNA.  
 
 
3.2.4 - Simultaneous siRNA-mediated knockdown of BRCA2 and TS induces 
complementary lethality to cisplatin, melphalan and both TS-targeting drugs 
 Since single siRNA treatment promoted the efficacy of different sets of drugs 
(e.g., TS siRNA and pemetrexed, BRCA2 siRNA and cisplatin), I assessed whether 
transfecting BRCA2 and TS siRNA simultaneously sensitized A549 cells to the 
entire panel of 4 chemotherapeutic drugs. My aim was to investigate whether 
combination siRNA treatment could be utilized to induce complementary lethality 
to both alkylating drugs and TS targeting agents, and whether the magnitude of 
sensitization would exceed that induced by each individual siRNA to its "non-
complementary"  drug partner (e.g., TS siRNA and cisplatin).  
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A549 cells were transfected with control siRNA, BRCA2 siRNA and/or TS 
siRNA and subsequently treated with cisplatin 24 hours later. Ninety-six hours post 
transfection the combination siRNA treatment potentiated the effects of cisplatin by 
46.3% ± 9.9% (p=0.002) compared to control siRNA treatment, and was 41.2% ± 
10.9% (p=0.002) more effective at growth inhibition following drug treatment than 
TS siRNA alone (Figure 11A).  
In addition, simultaneous BRCA2 and TS siRNA treatment sensitized 
human A549 cancer cells to melphalan treatment by 60% ± 0.8% (p=2.4x10-7) 
more than control siRNA treatment, and 56% ± 1% (p=1.0x10-6) more than TS 
siRNA (Figure 11B). 
Combination siRNA treatment sensitized A549 cells to 5-FUdR by 59.2% ± 
5.1% (p=0.0001) and was 43.0% ± 7.1% (p=0.0005) more effective at sensitization 
than single BRCA2 siRNA treatment (Figure 11C), even though BRCA2 siRNA 
also potentiated 5-FUdr toxicity on its own as shown previously.  
Furthermore, combined BRCA2 and TS siRNA transfection potentiated the 
efficacy of pemetrexed by 56% ± 3.3% (p=0.0004) more than control siRNA 
treatment, and was 56.4% ± 3.3% (p=1.0x10-5) more effective at drug sensitization 
than BRCA2 siRNA alone (Figure 11D). The above experiments were repeated in 
HeLa cells and yielded results of similar magnitude and scope (Figure 12A-D). 
These results show that combination BRCA2 and TS siRNA treatment induces 
complementary lethality to a broader panel of chemotherapeutic agents and 
creates multi-drug sensitive tumors. They also suggest that combination siRNA 
treatment and combination drug treatment may be an effective way to maximize 
chemotherapeutic efficacy of different classes of drugs.       
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Figure 11 - Simultaneous siRNA-mediated knockdown of BRCA2 and TS induces 
complementary lethality to cisplatin, melphalan, and both TS-targeting drugs in 
A549 cells. A549 cells were transfected with control, TS and/or BRCA2 siRNA and, at 
24 h post-transfection, treated with (A) cisplatin, (B) melphalan, (C) 5-FUdR or (D) 
pemetrexed. Effects on cell proliferation were determined by direct cell counting at 96 h 
and calculated as a percentage of non-drug treated, control siRNA transfected 
cells.*Different from cells treated with control non-targeting siRNA and drug ( p<0.05). 
**Different from cells treated with single siRNA and drug (p<0.05). Representative data 
from one of three independent experiments is shown (mean ± SD).  
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Figure 12 - Simultaneous siRNA-mediated knockdown of BRCA2 and TS induces 
complementary lethality to cisplatin, melphalan, and both TS-targeting drugs in 
HeLa cells. HeLa cells were transfected with control, TS and/or BRCA2 siRNA and, at 
24 h post-transfection, treated with (A) cisplatin, (B) melphalan, (C) 5-FUdR or (D) 
pemetrexed. Effects on cell proliferation were determined by direct cell counting at 96 h 
and calculated as a percentage of non-drug treated, control siRNA transfected 
cells.*Different from cells treated with control non-targeting siRNA and drug (p<0.05). 
**Different from cells treated with single siRNA and drug (p<0.05). Representative data 
from one of two independent experiments is shown (mean ± SD).  
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3.2.5 - Simultaneous downregulation of BRCA2 and TS in the same cell population 
induces complementary lethality to two different sets of drugs and increases overall 
treatment effectiveness 
 Combined treatment with TS-targeting and platinum-based anticancer 
drugs is standard of care for a variety of common and important human cancers 
[97, 98]. Therefore, antisense-mediated enhancement of these drug combinations 
is desirable and potentially valuable therapeutically. Given that complementary 
lethality was separately induced to cross-linking agents and TS targeting drugs by 
combined TS and BRCA2 siRNA treatment, I next determined whether combined 
complementary lethality to both types of drugs could be induced simultaneously in 
the same cell population and if the magnitude of drug potentiation by this regimen 
could further decrease cancer cell proliferation.   
 A549 cells were transfected with control siRNA and combination BRCA2 
and TS siRNA. Twenty-four hours post transfection, the cells were treated with 
either cisplatin, 5-FUdR or both drugs simultaneously, and effects on proliferation 
were enumerated 96 hours post transfection.  
 Combination siRNA treatment potentiated the effects of combination 
cisplatin and 5-FUdR treatment by 64.1% ± 7% (p=0.0001) relative to control 
siRNA treatment. This showed that complementary lethality to two different drugs 
could be induced in the same cell population with combination siRNA treatment. 
Furthermore, the overall magnitude of this approach was more effective at reducing 
overall cell number compared to non-drug treated control than combination siRNA 
transfection and treatment with any single drug (p=<0.05), suggesting that there is 
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potential therapeutic benefit to sensitizing to cisplatin and 5-FUdr in the same cell 
population (Figure 13A).  
 To determine whether the same phenomenon could be reproduced with 
another drug whose toxicity was potentiated by BRCA2 siRNA, the experiment was 
repeated with melphalan substituted for cisplatin. Again, combined siRNA 
treatment effectively sensitized to combined drug treatment relative to control 
siRNA (47.4% ± 4.6%, p=0.0006) and the final outcome in terms of cell proliferation 
was superior to treatment with combination siRNA and any single drug (p=<0.05) 
(Figure 13B).  
Interestingly, though combination siRNA transfection still sensitized to 
combination cisplatin and pemetrexed treatment (52.8% ± 2.9%, p=5.6x10-5), it did 
not result in a larger decrease in cell proliferation than combination siRNA 
transfection and pemetrexed treatment alone (Figure 13C). Concomitant cisplatin 
and pemetrexed treatment also failed to induce an additive effect on cell growth, 
unlike that seen with cisplatin and 5-FUdR, and melphalan and 5-FUdR.  
The experiments with cisplatin plus 5-FUdR, and melphalan plus 5-FUdR 
were repeated in HeLa cells to establish the generalizability of the phenomenon. 
The results obtained using HeLa cells mirrored those in A549 cells (Figure 14A&B) 
and again showed that combined complementary lethality to two separate drugs in 
the same cell population is of potential therapeutic benefit. 
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Figure 13 - Combined complementary lethality to two different drugs in the 
same cell population can be achieved by combined BRCA2 and TS siRNA 
transfection in A549 cells. A549 cells were transfected with control, TS and/or 
BRCA2 siRNA and treated with (A) cisplatin, 5-FUdR, or cisplatin plus 5-FUdR, (B) 
melphalan, 5-FUdR or melphalan plus 5-FUdR, and (C) cisplatin, pemetrexed, or 
cisplatin plus pemetrexed. Black bars = cells untreated with drugs (A,B,C), white bars 
= treatment with cisplatin (A,C) or melphalan (B). Patterned white bars = cells treated 
with 5-FUdR (A,B) or pemetrexed (C) ; dark grey bars = cells treated with 
combinations of drugs (A,B,C). Cell proliferation was measured 96 h post-transfection 
and is shown as a percentage of cells treated with control non-targeting siRNA alone. 
**Different from cells treated with drug combination and control non-targeting siRNA 
(p<0.05). *Different from cells treated with combined siRNA, and one drug or no drug 
(p<0.05).  Representative data from one of two independent experiments is shown 
(mean ± SD). 
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Figure 14 - Combined complementary lethality to two different drugs in the 
same cell population can be achieved by combined BRCA2 and TS siRNA 
transfection in HeLa cells. HeLa cells were transfected with control, TS and/or 
BRCA2 siRNA and treated with (A) cisplatin, 5-FUdR, or cisplatin plus 5-FUdR, (B) 
melphalan, 5-FUdR or melphalan plus 5-FUdR. Black bars = cells untreated with 
drugs (A,B), white bars = treatment with cisplatin (A,C) or melphalan (B). Patterned 
white bars = cells treated with 5-FUdR (A,B); dark grey bars = cells treated with 
combinations of drugs (A,B). Cell proliferation was measured 96 h post-transfection 
and is shown as a percentage of cells treated with control non-targeting siRNA alone. 
**Different from cells treated with drug combination and control non-targeting siRNA 
(p<0.05). *Different from cells treated with combined siRNA, and one drug or no drug 
(p<0.05).  Representative data from one of two independent experiments is shown 
(mean ± SD). 
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Chapter 4. BRCA2 Inhibition enhances cisplatin-mediated alterations in 
tumor cell proliferation, metabolism, and metastasis 
4.1 Preamble: 
A high rate of mutation and genetic instability can be considered 
fundamental hallmarks of cancer that distinguish tumor cells from their normal 
counterparts [83, 85, 86]. Lack of integrity in the cancer genome is often 
precipitated by compromised or incomplete DNA repair, reliance on error-prone 
repair, and/or defects in cell cycle control [1].  This renders cancer cells susceptible 
to DNA damage-induced toxicity, and is at least partly responsible for the difference 
between non-tumor cells and cancer cells in sensitivity to DNA-damaging 
therapeutic agents. 
 However, genomic heterogeneity and mutability also underlie tumor cell 
adaptability and acquired resistance to chemo- and/or radiotherapy [7]. Thus, the 
same traits that render cancer cells more susceptible to DNA-damaging 
therapeutics can also lead to treatment failure. Tumor cells must preserve a level 
of DNA repair sufficient to maintain survival in the face of selection pressures 
posed by treatment, but sufficiently limited to permit enhanced adaptability [99]. 
This dichotomy can be exploited for therapeutic benefit. Inhibiting DNA repair may 
push tumor cells past a tolerable threshold of DNA damage and induce cell death, 
thus preventing further heterogeneity and the development of acquired drug 
resistance. 
Cisplatin is a platinating drug commonly used to treat various types of solid 
malignancies [100]. However, the associated toxicities and both inherent and 
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acquired resistance can limit the effectiveness of these drugs in the clinic [55]. 
Strategies to render cancer cells more sensitive to platinum agents are therefore 
of high clinical importance.  
Patients with tumors harboring BRCA2 mutations have an improved 
prognosis following treatment with platinum-containing drugs, compared to 
patients with tumors with intact BRCA2 genes [101, 102]. In addition, BRCA2 
mutation status leads to differences in metastatic frequency in patients [22, 
103].This suggests that actively targeting BRCA2 in cancer cells with functional 
HRR may render cisplatin treatment more effective. 
  Based on proof-of-concept studies described in chapter 3 [47], I developed 
a second generation BRCA2-targeting antisense oligodeoxynucleotide (ASO). I 
investigated the potential therapeutic value of the BRCA2 ASO in a setting with 
concomitant cisplatin treatment by determining the effects on tumor cell 
proliferation, metabolic response, and metastasis. In this chapter I show that 
BRCA2 ASO plus cisplatin treatment is potentially valuable clinically, and describe 
a new role for BRCA2 in the maintenance of human tumor cell metabolic response 
and metastasis frequency following cisplatin treatment. 
 
4.2. Results: 
4.2.1 - Mutations in the BRCA2 gene positively impact patient prognosis 
 Using the cBioPortal for Cancer Genomics I analyzed the effect of mutations 
in the BRCA2 gene on cancer patient survival [104]. Both endometrial and ovarian 
cancers were investigated to assess the consequences of naturally-occurring 
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BRCA2 mutations on survival in patient populations, as BRCA2 mutations were 
reasonably common in these tumor types and the availablity of TCGA was 
relatively high. A query of the TCGA Uterine Endometrial Carcinoma (UEC) dataset 
[77] revealed a higher disease-free survival (logrank p = 0.032) and a trend to 
higher overall survival (logrank p = 0.10) in patients with BRCA2 alterations (Figure 
15A). However, survival of endometrial carcinoma patients with wild type BRCA2 
was relatively high, diminishing the power to detect survival differences.  
 BRCA2 mutations were queried against survival using the TCGA Ovarian 
Serous Cystadenocarcinoma dataset (Cancer Genome Atlas Research Network, 
[105] in which overall 5 year survival was 40% or less. As opposed to analyzing 
the combined effect of BRCA1 and BRCA2 mutations on outcome (Cancer 
Genome Atlas Research Network, [105], my analysis correlated changes in 
BRCA2 alone with improved overall  (72.9 vs 43.3 months, logrank p =0.002) and 
disease-free (26.2 vs 15.4 months, logrank p = 0.014) survival (Figure 15B). No 
such correlation was found for BRCA1 gene mutations (Figure 15C). Overall, 
naturally-occurring BRCA2 mutations in at least two tumor types (of the 
endometrium and ovary) trend toward or are significantly associated with increased 
survival. That association supports the hypothesis that BRCA2 may be a 
therapeutic target to enhance anticancer therapy.   
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Figure 15 - Retrospective analysis of patient survival data based on BRCA2 mutation 
status. The TCGA Uterine Endometrial Carcinoma dataset was queried using the cBio 
Portal to determine changes in disease-free  and overall survival (A) in patients with 
alterations in BRCA2 (BRCA2 WT N = 215, BRCA2 mut N = 24). The TCGA Ovarian 
Serous Cystadenocarcinoma dataset was queried to determine changes in disease-free 
and overall survival in patients with alterations in BRCA2 (WT N = 276, mut N = 39) (B) or 
BRCA1 (WT N = 277, mut N = 38) (C). Red line = mutant BRCA1 or BRCA2, Blue line = 
WT BRCA1 or BRCA2 
A 
B 
C 
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4.2.2 - BRCA2 ASO treatment decreases target mRNA, protein and RAD51 focus 
formation 
 Transfection of A549 non-small cell lung cancer cells with BRCA2 ASO 
decreased BRCA2 mRNA by 78% and reduced BRCA2 protein levels (Figure 
16A&B). BRCA2 ASO also negatively impacted BRCA2 function on a cellular level, 
as shown by decreased RAD51 focus formation induced by subsequent cisplatin 
treatment (Figure 16C). Thus, the degree of BRCA2 ASO-induced target 
downregulation was sufficient to reduce at least one BRCA2 function important in 
HRR.  
 
4.2.3 - BRCA2 maintains tumor cell proliferative capacity following cisplatin 
treatment 
 To determine the effect of BRCA2 knockdown on tumor cell response to 
cisplatin, I transfected A549 cells with BRCA2 ASO and treated with cisplatin. The 
effectiveness of cisplatin was increased as much as 50 ± 3% (p<0.05) in cells 
transfected with BRCA2 ASO compared with control (Figure 17A and 18A).  
 BRCA2 ASO sensitized A549 cells to melphalan, another DNA cross-linking 
agent, by 45 ± 2% (p<0.05) compared to cells transfected with control ASO (Figure 
17B and 18B). BRCA2 ASO treatment also rendered cisplatin more effective in 
SKOV-3 ovarian cancer cells (55% ± 3%, p<0.05) and in MDA-MB-231 breast 
cancer cells (26% ± 8%, p<0.05), confirming that this phenomenon is reproducible 
in human tumor cell lines of differing origin (Figure 17C&D).  
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Figure 16 - BRCA2 ASO decreases BRCA2 mRNA, protein, and RAD51 foci 
formation frequency in A549 cells. A) A549 cells were transfected with 20 nM BRCA2 
ASO and total cellular RNA was isolated 24 hours later. Relative BRCA2 mRNA levels 
(mean ± SD) were assessed with RT-qPCR. B) BRCA2 protein levels were assessed 72 
hours after BRCA2 ASO transfection. C) RAD51 focus formation (mean ± SD) was 
quantified 48 hours after BRCA2 ASO transfection (p<0.05). 
A B 
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Figure 17 - BRCA2 regulates cisplatin-induced reduction of lung, ovarian and breast 
tumor proliferation. A549 cells were treated with varying concentrations of cisplatin (A) or 
melphalan (B) and control (black circles) or BRCA2 (white circles) ASO. Cells were counted 
96 hours post transfection to assess effects of BRCA2 knockdown. SKOV-3 cells (C) and 
MDA-MB-231 cells (D) were treated with different concentrations of cisplatin and control or 
BRCA2 ASO, and counted 96 hours post transfection.  *Different from cells treated with control 
ASO (p<0.05). Representative results from one of two experiments 
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Figure 18 - BRCA2 knockdown modulates cisplatin- or melphalan-induced A549 
cell proliferation. A549 cells were treated with varying concentrations of A) cisplatin or 
B) melphalan, following transfection with control (black circles) or BRCA2 (white circles) 
ASO. Effects on cellular proliferation were determined using the turnover of AlamarBlue 
reagent as the readout. *Different from cells treated with control ASO using a Student's 
t-test (p<0.05). 
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Somatic BRCA2 mutations predispose human cells to malignant 
transformation [20]. In addition, since BRCA2 knockdown may enhance toxicity of 
DNA-damaging drugs to normal, non-tumor cells, I investigated the effect of 
BRCA2 ASO on cisplatin toxicity in human non-tumor HK-2 kidney cells. Treatment 
of HK-2 cells with BRCA2 ASO induced only a small increase in sensitivity to 
cisplatin (12% ± 6%) (Figure 19A).  
 Human pancreatic CAPAN-1 cells, which lack a functional BRCA2 protein 
[106], were subjected to the same BRCA2 ASO/cisplatin treatment. There was no 
increase in cisplatin sensitivity in CAPAN-1 cells following BRCA2 ASO 
transfection (Figure 19B), suggesting that the effects of BRCA2 knockdown with 
BRCA2 ASO seen in tumor cell lines are due to BRCA2 downregulation and not 
off-target events.  
 
4.2.4 - BRCA2 downregulation reverses acquired cisplatin resistance in head and 
neck tumor cells 
  To assess the effectiveness of BRCA2 downregulation in reversing 
acquired cisplatin resistance in human tumors, I tested cisplatin sensitivity in three 
human head and neck squamous carcinoma cell lines [76]: HN-5a, HN-5a/carbo-
10a, and HN-5a/carbo-15a (Figure 20A).  
 BRCA2 ASO treatment potentiated cisplatin in parental HN-5a cells by 63 ± 
5% and cisplatin-resistant HN5a-carbo-15a cells by 57 ± 2% (Figure 20B&C).  The 
resulting sensitivity generated by BRCA2 ASO transfection was similar to that of 
parental HN5a cells (Figure 20C). Although HN-5a/carbo-15a cells exhibit  
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Figure 19 - BRCA2 does not affect cisplatin-induced proliferation changes in non-
cancerous cells and cells without BRCA2 function. A) Non-tumor HK-2 kidney cells 
were treated with two concentrations of cisplatin and control or BRCA2 ASO, and relative 
proliferation was quantified using cell counting 96 hours post transfection. B) BRCA2 
deficient CAPAN-1 cells were exposed to varying concentrations of cisplatin and control 
or BRCA2 ASO, and counted 96 hours post transfection. *Different from cells treated with 
control ASO (p<0.05). Representative results from one of two experiments 
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Figure 20 - BRCA2 ASO reverses acquired cisplatin resistance in human head and 
neck cancer cells. A) HN-5a, HN5a/carbo-10a, and HN-5a/carbo-15a cells were 
exposed to cisplatin and effects on proliferation were assessed 72 hours after drug 
treatment. HN-5a cells (B) and HN-5a/carbo-15a cells (C) were transfected with control 
(black circles) or BRCA2 (white circles) ASO, treated with varying concentrations of 
cisplatin and then counted 96 hours post transfection. *Different from cells treated with 
control ASO using a Student's t-test (p<0.05). Representative results from one of two 
experiments.  
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decreased intracellular accumulation of cisplatin compared to the parental HN-5a 
cell line [76], BRCA2 downregulation was still able to effectively sensitize cells to 
cisplatin.  
 An assay of in vitro colony formation was used as a more stringent measure 
of the long term effects of treatment on seeding potential [107]. Treatment with 
BRCA2 ASO and cisplatin decreased colony formation ability in both HN-5a and 
HN-5a/carbo-15a cells (Figure 21A&E), suggesting that BRCA2 inhibition can 
enhance the ability of cisplatin to limit cancer cell proliferation and colony forming 
potential. 
 
4.2.5 - BRCA2 modulates tumor cell metabolism following cisplatin treatment 
 Given the dependence of DNA maintenance and repair on functional 
metabolic processes [108], it was possible that at part of the BRCA2 ASO-
mediated increase in cisplatin cytotoxicity was due to alterations in cellular 
metabolism. In addition, cisplatin has been shown to preferentially target 
mitochondrial DNA in tumor cells [109]. To investigate, I measured changes in cell 
impedance, acidification and oxygen consumption associated with BRCA2 ASO 
and cisplatin treatment to determine monolayer integrity, cellular glycolytic activity, 
and respiration [54]. 
 After 24 h exposure to cisplatin, A549 tumor cells pre-treated with BRCA2 
ASO had 39% less respiratory activity than cells pre-treated with control ASO. 
Furthermore, in BRCA2 ASO treated cells, the respiration decrease was evident 
10 h after addition of cisplatin and 15 h earlier than in cells treated with control ASO  
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Figure 21 - BRCA2 ASO decreases colony forming ability of human head and 
neck cancer cells following cisplatin treatment. HN5a cells (A) and HN15a cells 
(B) were transfected with control or BRCA2 ASO, treated with different 
concentrations of cisplatin for 6 hours, and then re-plated at a density of 500 cells per 
well to determine colony forming ability. *Different from cells treated with control ASO 
using a Student's t-test (p<0.05).  
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(Figure 22A). Respiration began to decrease in response to cisplatin in BRCA2-
treated cells 10 h prior to observable reduction in adhesion, suggesting that 
respiration reduction occurred independent of changes in cell number or viability 
(Figure 22B). However, no difference in acidification (a measure of glycolysis) was 
observed between the BRCA2 ASO and control ASO groups treated with cisplatin 
(Figure 22C).  
  Changes in cellular respiration induced by BRCA2 ASO in conjunction with 
cisplatin suggested BRCA2 ASO-mediated inhibition of mitochondrial function. I 
used mitochondria-specific dye accumulation to determine the frequency of 
functional mitochondria in A549 and HN-5a cells, and changes in those parameters 
induced by BRCA2 ASO plus or minus cisplatin. Cisplatin treatment induced a 63% 
increase in Mitotracker staining in both A549 and HN5a cells. However, there was 
no difference in staining between cells treated with BRCA2 ASO plus cisplatin and 
control ASO plus cisplatin (Figure 23A and 24A).  
 Cellular glucose uptake is modulated by cisplatin treatment and DNA 
damage [110]. I observed that cisplatin treatment of A549 cells increased glucose 
uptake by 60%. Pretreatment with BRCA2 ASO increased that response to 
cisplatin by a further 17% (Figure 23B and 24B). This raised the possibility that 
increased glucose entry induced by cisplatin after BRCA2 reduction might be a 
cellular response to generate additional energy necessary for increased DNA 
repair. However, decreased acidification induced by cisplatin (a measure of 
reduced glycolysis [54]) was approximately the same regardless of ASO treatment 
(Figure 22C). This suggests that the BRCA2 ASO-induced increase in glucose 
uptake in response to cisplatin was not sufficient to enhance glycolytic activity.  
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Figure 22 - BRCA2 modulates tumor cell respiration following cisplatin 
treatment. A549 cells were exposed to cisplatin (6 µM, 24 hours) following a six hours 
of incubation in medium to determine baseline metabolic levels. At 24 hours after 
addition of cisplatin, medium was exchanged for free medium without cisplatin. 
Measurements of oxygen consumption (A), impedance (B), and changes in medium 
pH (C) were conducted. Representative results from one of three experiments.  
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Figure 23 - BRCA2 modulates tumor cell glucose uptake following cisplatin 
treatment. A549 cells were transfected with control or BRCA2 ASO and then 
treated with cisplatin (6µM). Mitotracker staining (A) and glucose uptake (B) were 
determined using flow cytometry. *Different from cells treated with control ASO 
using a Student's t-test (p<0.05). Representative results from one of two 
experiments 
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Figure 24 - BRCA2 knockdown in HN-5a cells enhances cisplatin-induced 
glucose uptake but not Mitotracker-measured mitochondrial function. HN-5a 
cells were transfected with control or BRCA2 ASO and then treated with cisplatin 
(6µM). Mitotracker staining (A) and glucose uptake (B) were determined using flow 
cytometry. *Different from cells treated with control ASO using a Student's t-test 
(p<0.05). 
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Furthermore, the loss of adhesion (indicative of a decrease in cell monolayer 
integrity [54]) in response to cisplatin in cells treated with BRCA2 ASO indicates 
that increased glucose uptake was not capable of rescuing cells from BRCA2 ASO-
mediated sensitization to cisplatin (Figure 22B).  
 
4.2.6 - BRCA2 inhibition decreases metastatic frequency following cisplatin 
treatment  
 The majority of cancer patients do not die from primary disease, but instead 
succumb to metastatic tumors. I therefore investigated whether concomitant 
BRCA2 ASO and cisplatin treatment would decrease the number of metastatic foci 
to a higher degree than cisplatin alone, since there is some evidence linking 
BRCA2 mutation status to metastasis in cancer patients [22, 103].  
 To ensure that the long term effects of treatment were reproducible in A549 
cells before investigating metastasis directly, I conducted an in vitro colony 
formation assay. Colony formation by A549 cells treated with BRCA2 ASO and 
cisplatin (6 µM) was reduced by 48 ± 4% (p<0.05) compared to cells treated with 
control ASO and cisplatin (Figure 25A). BRCA2 downregulation also decreased 
the ability of A549 cells to form colonies following gamma irradiation (Figure 25B), 
in accord with previous reports [110].  
 To extend my findings to a metastatic context I utilized the chicken 
chorioallantoic membrane (CAM) invasion assay, and determined the effects of 
treatment on metastatic focus formation [111, 112]. A549-GFP cells were treated 
with control or BRCA2 ASO in the presence of absence of cisplatin, and then  
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Figure 25 - BRCA2 regulates tumor cell colony forming ability following 
cisplatin treatment. A549 cells were transfected with control (black) or BRCA2 
(white) ASO and then exposed to varying concentrations of cisplatin (A) or different 
doses of ionizing radiation (B). Six hours after treatment, the capacity of cells to 
form colonies in vitro was determined. * Different from cells treated with control ASO 
(p<0.05). Representative results from one of two experiments 
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Figure 26 - BRCA2 regulates tumor cell metastatic frequency following 
cisplatin treatment in vivo. A549-GFP cells were transfected with control or 
BRCA2 ASO, treated with 6µM cisplatin for 6 hours, then injected i.v. into the 
CAM (Left and Center panel). Metastatic foci were counted 7-9 days following 
injection (Right panel) (n≥6 per group). * Different from cells treated with control 
ASO (p<0.05).  
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injected i.v. into CAM veins. Treatment of A549-GFP cells with BRCA2 ASO alone 
produced a trend toward decreased metastatic focus frequency. Ccombined 
BRCA2 ASO and cisplatin treatment reduced the frequency of metastatic focus 
formation by 77 ± 7% (p<0.05) relative to cisplatin alone (Figure 26). These data 
indicate that intact BRCA2 function limits the ability of cisplatin to modulate tumor 
cell metastatic frequency in the CAM model. 
 
Chapter 5. Reciprocal positive selection for weakness - overcoming 
olaparib resistance 
 
5.1 Preamble:  
 Tumor heterogeneity, which is a feature of most solid human tumors, renders 
therapeutic resistance a mathematical certainty due to the presence of minute 
numbers of resistant cells at the start of therapy; this phenomenon has been 
described using experiment models in vitro and has also been modelled in silico 
using data from clinical studies [10, 12]. Single nucleus genome sequencing of 
breast cancer specimens has shown that no two cancer cells in a tumor are exactly 
the same [9], highlighting the challenge to effective and long-term anti-cancer 
therapy.  
 Cytotoxic and targeted therapies impose powerful selection pressure on the 
polyclonal and diverse tumor ecosystem. As a result, this promotes the survival of 
cells with the highest fitness and destroys the weak (or susceptible cells), which 
leads to eventual therapeutic failure and is in line with classical Darwinian 
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evolutionary theory [113]. It is necessary therefore, to design a treatment regimen 
which reverses Darwinian positive selection and, instead of positively selecting for 
strength in the population, selects for weakness.  
PARP-1 inhibitors such as olaparib are selectively effective in tumors with 
homologous recombination repair (HRR) deficiency [52]. This occurs primarily due 
to the inability of HRR-deficient tumor cells to repair double-strand DNA breaks 
(DSBs) that result when PARP1 inhibition prevents resolution of single-strand 
breaks (SSBs) [63]. However, the selective killing of tumor cells with HRR defects, 
an attractive therapeutic goal for PARP inhibitors, ultimately contributes to reduced 
effectiveness [74]. First, HRR-deficient tumors, against which PARP1 inhibitors are 
most useful, are present in only a subset of cancer patients [65]. Second, selective 
killing in a heterogeneous tumor population leads to outgrowth of resistant clones 
and therapy failure, a phenomenon already described for PARP-1 inhibitors [74].  
 Combining PARP1 inhibition with BRCA2 inhibition may be an avenue to 
prevent resistance, via a mechanism I termed “reciprocal positive selection for 
weakness”. In a heterogeneous tumor population, BRCA2 inhibition will select for 
cells with deficient HRR, while concomitant olaparib treatment will eliminate those 
cells. The reciprocal is also true: olaparib treatment will select for HRR-proficient 
cells, which will then be susceptible to BRCA2 inhibition. I hypothesize that such a 
strategy will prevent the outgrowth of resistant lesions and extend the time that a 
tumor is responsive to treatment.   
 In this chapter, I show that BRCA2 inhibition sensitized lung, ovarian and 
breast tumor cell lines to the PARP-1 inhibitor olaparib. Importantly, BRCA2 ASO 
treatment did not increase the susceptibility of non-cancerous HK-2 kidney and 
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HCC-841 colon cell lines to PARP-1 inhibition. Furthermore, combined BRCA2 
ASO and olaparib treatment in a tumor cell population with varying degrees of 
HRR-proficiency prevented the outgrowth of resistant clones. In addition, I found 
that combined inhibition of BRCA2 and PARP1 in vivo delayed the growth of 
ovarian cancer tumors. This work provides rationale for combining BRCA2 ASO 
and olaparib treatment and also extends the applicability of olaparib clinically, 
which up until now has been used primarily in the context of BRCA1/2 mutated 
ovarian cancers.    
 
5.2. Results 
5.2.1 BRCA2 inhibition overcomes innate olaparib resistance in three lung cancer 
cell lines 
 Olaparib has limited efficacy in cancer cells with intact HRR [114]. The 
majority of lung tumors do not exhibit mutations in BRCA1/2 genes (BRCA1/2 is 
mutated in 1.8%-11.2% of cases depending on the data set and tumor type) [104]. 
Thus, olaparib may have little utility in lung cancer treatment on its own. To 
determine whether BRCA2 inhibition could overcome innate olaparib resistance, I 
tested control or BRCA2 ASO treatment with increasing concentrations of olaparib 
in BRCA2-proficient A549 lung adenocarcinoma and H2052 and 211H 
mesothelioma cell lines.  
 All three cell lines harbor mutations (513 coding + 616 non-coding mutations 
in A549 cells; 402 coding + 509 non-coding mutations in 211H cells; and 80 coding 
77 
 
+ 76 non-coding mutations in H2052 cells) (Figure 27A), suggesting heterogeneity 
in each population. BRCA2 downregulation increased olaparib sensitivity by as 
much as 34.5% ± 2.8%, 31.9% ± 8.5%, and 44.1%± 7.8% (p<0.05)  in A549, 211H, 
and H2052 cells, respectively (Figure 27B-D). BRCA2 ASO treatment sensitized 
all three lung cancer cell lines to olaparib across the entire range of drug 
concentrations regardless of mutational signature and load, suggesting that 
BRCA2 inhibition may render lung tumors with disparate backgrounds amenable 
to PARP inhibition.   
 
5.2.2 BRCA2 inhibition sensitizes ovarian and breast cancer cells to olaparib 
treatment 
 Olaparib is approved by the FDA for treatment of BRCA1/2-mutated ovarian 
cancers [69]. However, only a fraction of ovarian tumors exhibit BRCA1/2 
mutations [104] and most ovarian cancer patients are not eligible for olaparib 
treatment. Overcoming innate olaparib resistance in ovarian cancer cells with WT 
BRCA1/2 is potentially valuable clinically.  
 I tested whether BRCA2 downregulation could sensitize two different ovarian 
cancer cell lines to olaparib treatment. BRCA2 ASO treatment sensitized SKOV-3 
cells to PARP1 inhibition by as much as 52.3% ± 2.7% (p<0.05) (Figure 28A) and 
CaOv3 cells by 41.3% ± 9.9% (p<0.05) (Figure 28B). Although SKOV-3 cells were 
sensitized more than CaOV3 cells, the amount of antisense-mediated BRCA2 
knockdown was greater than 90% in both cell lines, similar to the amount of BRCA2 
reduction in H2052 and 211H mesothelioma cells (Figure 28C). 
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Figure 27 – BRCA2 inhibition overcomes innate olaparib resistance in three 
human lung cancer cell lines. A mutation heat map for each cell line was generated 
using the COSMIC CCLE database interface (A). A549 (B), 211H (C), and H2052 (D) 
cells were transfected with control ASO (●) or BRCA2 ASO (○) and then treated with 
three different concentrations of olaparib. Proliferation was determined by cell 
counting 96 hours post-transfection (*p<0.05). Means ± SD from representative 
experiments are shown. All experiments were repeated at least once. 
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Figure 28 – BRCA2 inhibition sensitizes ovarian cancer cell lines to olaparib 
treatment. SKOV-3 (A) and CaOV3 (B) cells were transfected with control ASO (●) or 
BRCA2 ASO (○) and then treated with three different concentrations of olaparib. 
Proliferation was determined by cell counting 96 hours post-transfection (*p<0.05).  C) 
BRCA2 mRNA levels were measured by qPCR 24 hours following BRCA2 ASO 
transfection in SKOV-3, CaOV3, 211H and H2052 cell lines. Cell counts were performed 
96 hours post transfection (*p<0.05). Means ± SD from representative experiments are 
shown. All experiments were repeated at least once.  
 
C 
80 
 
Furthermore, I tested whether BRCA2 ASO could sensitize triple-negative 
(estrogen receptor (ER), progesterone receptor (PR), and Her2/neu [9]) MDA-MB-
231 human breast cancer cells to olaparib. Treatment options for triple-negative 
breast cancer are limited [115] and decreasing innate olaparib resistance by 
BRCA2 downregulation could reveal a new path to more effective treatment. MDA-
MB-231 cells were rendered as much as 28.0% ± 5.1% (p<0.05) more sensitive to 
olaparib compared to cell treated with control ASO (Figure 29A). 
 To determine whether cells that survived the initial BRCA2 ASO and olaparib 
treatment remain sensitive to subsequent treatment, I treated the same cells with 
BRCA2 ASO and olaparib a second time. I found that single BRCA2 ASO + 
olaparib treatment hindered the proliferation of cells which were re-seeded without 
any additional olaparib treatment. In addition, a second round of BRCA2 ASO + 
olaparib treatment decreased SKOV-3 cell proliferation by 67.0% ± 12.4% (p<0.05) 
compared to cells which did not receive this second olaparib treatment (Figure 
29B). This suggests that cells which survive the first round of BRCA2 ASO + 
olaparib treatment are still amenable to a second treatment, which will continue to 
decrease their proliferation. 
 
5.2.3 BRCA2 inhibition does not sensitize non-cancerous cells to olaparib  
An important question when inhibiting BRCA2 in the context of olaparib 
treatment is whether non-cancer cells are affected to the same degree as tumor 
cells. It would be undesirable to increase sensitivity to olaparib in all host tissues.  
 Non-cancer, BRCA2-positive HK-2 kidney proximal tubule epithelial cells 
were transfected with either control ASO or BRCA2 ASO and treated with three  
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Figure 29 – BRCA2 inhibition sensitizes MDA-MD-231 breast cancer cells to 
olaparib treatment, and continues to sensitize ovarian cancer cells to repeated 
treatment doses. A) MDA-MB-231 breast cancer cells were transfected with control 
or BRCA2 ASO, treated with olaparib, and proliferation determined as described 
above. B) SKOV-3 cells were transfected with control or BRCA2 ASO and then treated 
with olaparib 24 hours post transfection. Ninety-six hours post transfection, cells were 
counted, plated, and re-transfected with control ASO or BRCA2 ASO and re-treated 
with olaparib. Cell counts were performed 96 hours post transfection (*p<0.05). Means 
± SD from representative experiments are shown. All experiments were repeated at 
least once.  
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concentrations of olaparib. BRCA2 inhibition did not sensitize HK-2 cells to olaparib 
at the tested concentrations (Figure 30A). BRCA2 mRNA downregulation was 
confirmed by qPCR to ensure that lack of sensitization was not due to inadequate 
transfection (Figure 30B). The experiment was repeated using non-cancer CCD-
841 colon epithelial cells and BRCA2 ASO treatment did not increase the potency 
of olaparib at any tested concentration (Figure 30C). 
 
5.2.4 BRCA2 ASO and Olaparib treatment induces changes in copy number and 
chromosomal translocation frequency in ovarian cancer cells 
  
Failure of the spindle assembly checkpoint (SAC) results in abnormal 
chromosomal segregation and can lead to fatal chromosome gain or loss in 
daughter cells [116]. Both BRCA2 and PARP1 support SAC in mitotic cells [50] 
and I hypothesized that the decreased proliferation following inhibition of both 
targets may be due to perturbation of SAC.  
 I investigated the effect of BRCA2 ASO and olaparib treatment on bulk 
chromosome number using metaphase spreads of SKOV-3 and MDA-MB-231 
cells. Twenty-four hours following olaparib or vehicle treatment, I identified a 
significant increase in the variance of the chromosome number in cells treated with 
BRCA2 ASO + olaparib (Figure 31A&B). This is consistent with the hypothesis 
that combined BRCA2 and PARP1 inhibition negatively affects the SAC and allows 
for the mis-segregation of chromosomes, leading to altered aneuploidy in daughter 
cells. 
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Figure 30 – Non-cancerous kidney and colon cell lines are not sensitized to 
olaparib by BRCA2 downregulation. Non-tumor HK-2 kidney proximal tubule 
epithelial cells (A) and CCD-841 fetal colon epithelial cells (B) were transfected with 
control or BRCA2 ASO and then treated with three different concentrations of 
olaparib. Proliferation was determined by cell counting 96 hours post-transfection 
(*p<0.05). C) BRCA2 mRNA levels in HK-2 cells were measured by qPCR following 
transfection of BRCA2 ASO. Means ± SD from representative experiments are 
shown. All experiments were repeated at least once. 
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Figure 31 – Combined BRCA2 ASO and olaparib treatment increases the 
variability in chromosome number in ovarian and breast cancer cells. SKOV-
3 (A) and MDA-MB-231 (B) cells were treated with control ASO or BRCA2 ASO in 
the presence or absence of olaparib. Forty-eight hours following olaparib treatment, 
cells were fixed and processed to yield metaphase spreads. The number of 
chromosomes in individual metaphase cells is shown. A', B': Mean chromosome 
number ± SD after each treatment, calculated from the data shown in panels A and 
B (*Difference in SD, p<0.05, Bartlett’s Test). 
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To determine whether BRCA2 ASO and olaparib treatment had an effect on 
genome stability I used whole chromosome FISH probes to label chromosomes X, 
3, and 16, and quantify the incidence of random translocations following treatment. 
Combined BRCA2 ASO + olaparib treatment led to 1.18 mean translocations per 
metaphase, compared to 0.1, 0.25 and 0.14 for other treatments (*p<0.05) (Figure 
32).   
  
5.2.5 Combined BRCA2 ASO and olaparib treatment can prevent resistance in a 
mixed cell line model with varying degrees of HRR 
 Human tumors exhibit a high degree of heterogeneity [10, 18, 61] which can 
lead to olaparib resistance [74]. Resistance can occur through a variety of 
mechanisms [73] including reversion to HRR-proficiency in tumors that were 
predominantly HRR-deficient prior to treatment [74, 75]. Due to the functional 
linkage between BRCA2 and PARP-1, I hypothesized that combined BRCA2 ASO 
and PARP inhibition would prevent reversion to HRR proficiency and the 
appearance of olaparib resistance.   
 To test this hypothesis, I used three human tumor cell lines with varying 
degrees of HRR proficiency: SKOV-3 (BRCA2 WT [117]), MCF-7 (HRR deficient 
[118]), and CAPAN-1 (BRCA2 mutant [117]). 
 When these three cell lines were treated with BRCA2 ASO (20 nM) 
simultaneously, the proliferation of HRR-proficient SKOV-3 cells was decreased by 
35% ± 10% (p<0.05) (Figure 33A). Thus, BRCA2 inhibition effectively reduced 
growth of HRR-proficient tumor cells. BRCA2 knockdown in HRR-deficient MCF-7 
and CAPAN-1 cells, on the other hand, had no negative effect on proliferation. 
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Figure 32 – Combined BRCA2 ASO and olaparib treatment increases 
translocation frequency in ovarian cancer cells. SKOV-3 cells were transfected with 
control ASO alone or with olaparib or BRCA2 ASO alone or with olaparib. Forty-eight 
hours post-olaparib, cells were processed to yield metaphase spreads. FISH was 
performed for chromosomes X, 3, and 16. The number of translocation events in these 
chromosomes was counted and graphed. Mean numbers of translocations for each 
treatment are shown as bars (–).*Mean number of translocations were significantly 
different (p<0.05, Welch’s t-test). Data from two pooled experiments are shown.  
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 These data support the hypothesis that BRCA2 downregulation in a mixed 
population of HRR-proficient and HRR-deficient cells would lead to an increased 
fraction of HRR-deficient, BRCA2 ASO-resistant cells (Figure 33A). When the cell 
fraction of a theoretical mixed population was calculated on the basis of relative 
proliferation after treatment with BRCA2 ASO, HRR-deficient MCF-7 and CAPAN-
1 cells increased in proportion from a total of 66% to 77% relative to SKOV-3 cells 
(Figure 33B). Thus, BRCA2 downregulation can select for HRR-deficient cells. 
On the other hand, treatment of each of the 3 cell lines with a single round 
of olaparib treatment decreased the proliferation of HRR-deficient MCF-7 and 
CAPAN-1 cells by 39% ± 6.8% and 94% ± 4.6% (p<0.05), respectively, but had no 
effect on SKOV-3 proliferation (Figure 33C). Based on these numbers, the fraction 
of HRR-proficient SKOV-3 cells in a theoretical mixed population after olaparib 
treatment increased from 33% to 61%. Thus, a single round of olaparib treatment 
can select for HRR-proficient cells, which is the reciprocal of the effect of BRCA2 
ASO.   
HRR-proficient SKOV-3 cells are resistant to olaparib relative to HRR-
deficient MCF-7 cells (Figure 34A). Combined treatment with BRCA2 ASO and 
olaparib abolished that relative resistance and led to a decrease in proliferation in 
both cell lines of 39% ± 0.1% and 40% ± 3.4% (p<0.05), respectively (Figure 34B). 
This suggests that simultaneous inhibition of BRCA2 and PARP-1 in 
heterogeneous tumor cell populations can prevent selection events and forestall 
emergence of treatment-resistant populations.  
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Figure 33 – Single treatment has the potential to select for HRR-deficient or HRR-
proficient cells, respectively. A) BRCA2-wild type SKOV-3 cells (black bars), HRR-
deficient MCF-7 cells (white bars), and BRCA2-mutated CAPAN-1 cells (grey bars) were 
treated simultaneously but separately with BRCA2 ASO (20 nM). Post-transfection (96 h), 
cells were counted and proliferation determined (% of proliferation after control ASO 
treatment). B) The theoretical proportions of a mixed cell population (HRR-proficient SKOV-
3 + MCF-7, and HRR-deficient CAPAN-1) following BRCA2 ASO treatment were calculated 
using the data shown in panel A. C) SKOV-3, MCF-7 and CAPAN-1 cells were treated with 
two different concentrations of olaparib for 96 hours. After drug treatment they were counted 
and proliferation was determined as a percent of that of vehicle-treated cells. D) The 
theoretical proportions of a mixed cell population following BRCA2 ASO treatment were 
calculated based on the experimental data shown in panel C. Data from representative 
experiments are shown. All experiments were repeated at least once. 
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proliferation of both HRR-deficient and HRR-proficient cells. BRCA2-wild type 
SKOV-3 cells (A) and HRR-deficient MCF-7 cells (B) were transfected with control 
ASO (black bars) or BRCA2 ASO (white bars) and treated with vehicle or olaparib 
(1 μM). Proliferation was determined using cell counting 96 hours post-transfection. 
Data from representative experiments are shown. All experiments were repeated at 
least once. 
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5.2.6 Combined BRCA2 ASO and olaparib treatment can prevent the outgrowth of 
resistant clones in a co-culture model of BRCA2 heterogeneity  
 To evaluate the effects of BRCA2 ASO and olaparib on population dynamics 
and resistance to treatment over time, I devised a co-culture model of SKOV-3 
ovarian cancer cells stably expressing either control shRNA or shRNA targeting 
BRCA2. This emulated a tumor population with different proportions of cells of 
varying HRR-proficiency. 
I determined how olaparib monotherapy would impact population dynamics 
in the context of varying HRR proficiency. To mimic a heterogeneous tumor cell 
population that is predominantly HRR-deficient, I co-cultured SKOV-3shBRCA2 (low 
BRCA2) and SKOV-3shcontrol (high BRCA2) in a 3:1 ratio. The mixed cell population, 
along with unmixed SKOV-3shBRCA2 and SKOV-3shcontrol populations, was treated 
with olaparib (1° Olaparib), then counted, re-seeded and treated with olaparib a 
second time (2° Olaparib), according to the experimental schematic (Figure 35). 
The mixed cell population, though sensitive to initial treatment with olaparib (Bar 9 
vs 10), was completely unresponsive to a second dose (Bar 11 vs 12) (Figure 
36A). The unmixed SKOV-3shBRCA2 population remained sensitive to olaparib even 
after two doses (Bar 7 vs 8) (Figure 36A). This suggests that 1° olaparib treatment 
of the mixed cell population selected for HRR-proficient cells and allowed them to 
outgrow HRR-deficient cells.  
To determine if combined BRCA2 ASO and olaparib treatment could 
forestall the development of resistance among mixed SKOV-3shBRCA2 and SKOV-
3shControl cells, the mixed and unmixed cells were treated with either control ASO or 
BRCA2 ASO, in the presence or absence of drug treatment. BRCA2 ASO 
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treatment sensitized the mixed cell population to olaparib (Bar 11 and 12), and the 
proliferation level of the mixed population following BRCA2 ASO and olaparib 
treatment was similar to that of the SKOV3shBRCA2 cells treated similarly (Bar 7 and 
8) (Figure 36B).  
When mixed and unmixed SKOV-3 populations treated with olaparib and 
either control ASO or BRCA2 ASO were re-seeded without any further treatment, 
the mixed cell population that had received BRCA2 ASO + olaparib was unable to 
proliferate (Figure 36C).  This suggests that simultaneous inhibition of both BRCA2 
and PARP1 can prevent the outgrowth of resistant cells in a tumor population with 
HHR heterogeneity. 
 
5.2.7 Combined inhibition of BRCA2 and PARP1 decreases ovarian tumor growth 
in vivo 
I determined whether combined BRCA2 and PARP1 inhibition could prevent 
or delay growth of ovarian tumors in vivo. Female athymic nude mice were injected 
with SKOV3-IP1 cells i.p and treated 7 days later with control siRNA or BRCA2 
siRNA in the presence or absence of olaparib. Following 7 weeks of treatment, 
mice were weighed (Figure 37A), euthanized, and dissected to determine the 
number and combined weight of tumor nodules in the peritoneal cavity. BRCA2 
siRNA + olaparib treatment decreased both the number (Figure 37B) and weight 
(Figure 37C) of tumors relative to BRCA2 siRNA or olaparib treatment alone 
(p<0.05), suggesting that combing BRCA2 reduction with PARP1 inhibition may be 
useful therapeutically to limit tumor growth.    
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Figure 35 – Schematic for mixed cell experiments. The mixed cell population, as 
well as the unmixed populations were treated according to the experimental 
schematic. The experiment was conducted in a serial and continuous fashion, such 
that all treatment groups and cell populations were in culture for the same amount of 
time, and all controls were exposed to the same conditions. 
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Figure 36 – Combined BRCA2 ASO and olaparib treatment prevents outgrowth of resistant 
cells in a tumor cell population heterogeneous for HRR-proficiency. A) SKOV-3shBRCA2 cells 
were mixed with SKOV-3shControl cells at a 3:1 ratio, resulting in a primarily HRR-deficient mixed 
cell population. Parental and mixed populations were treated for the first time with olaparib (1° 
olaparib, 2.5 μM) or vehicle. Cells were re-plated at equal density 96 hours post-treatment. 
Parental and mixed populations were treated a second time with olaparib (2° olaparib, 2.5 μM). 
Ninety-six hours post-treatment, proliferation for all groups was determined based on cell counts 
and seeding density following 1° olaparib or vehicle treatment. White bars: 2° olaparib. Black 
bars: no 2° olaparib.  B) SKOV-3shBRCA2 cells, SKOV-3shControl cells, and a mixed cell population 
(3:1 as above) were transfected with control ASO or BRCA2 ASO followed by treatment with 
vehicle or olaparib (2.5 μM). Proliferation (percent of control ASO-treated cells) was determined 
96 hours post-transfection. White bars: 2° olaparib. Black bars: no 2° olaparib. C) SKOV-3shBRCA2 
cells, SKOV-3shControl cells, and a mixed cell population (3:1 as above) previously treated with ASO 
(control or BRCA2) and olaparib (2.5 μM) were re-plated at the same density and allowed to 
proliferate without further treatment. Data from two pooled experiments are shown. 
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Figure 37 – BRCA2 inhibition sensitizes ovarian cancer tumors to olaparib treatment 
in vivo. Female athymic nude mice were injected with 1.0x106 SKOV3-IP1 cells i.p. Mice 
were treated 7 days later with olaparib (5 mg/kg 5 days a week i.p.) and either control or 
BRCA2 siRNA twice per week encapsulated in DOPC-liposomes (150 µg/kg) (N=40, 10 
animals per group). Once the mice in any group were moribund, the animals were weighed 
(A) and euthanized. The tumour weight (B) and number of tumour nodules (C) were 
determined (p*<0.05, Student’s t-test). 
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Chapter 6. Discussion 
Genomic instability, mutation, and the accompanying heterogeneity 
represent common traits among most human cancers [119]. However, and despite 
the fact that a high mutation rate is a driving factor behind malignant progression, 
lack of genomic fidelity can act as an 'Achilles heel' for tumor cells [28]. In the face 
of selection pressure (e.g., cytotoxic DNA-damaging therapy), all cancer cells must 
preserve a level of DNA repair that is sufficiently active to maintain their survival, 
but also sufficiently limited or error prone to allow continued mutability, adaptability, 
and heterogeneity on a tumor (population) level. Consequently, although cancer 
cells often exhibit compromised or inefficient DNA repair or cell cycle control, which 
in many cases is a driver of their malignant evolution and etiology [71, 120, 121], 
the level of DNA maintenance they continue to harbour is (by definition) adequate 
to keep the population alive -- the idea of cancer cell reliance on a limited number 
of DNA repair mediators for continued survival has important implications for 
cancer treatment.  
Thus, functional DNA repair machinery in a cancer cell constitutes an 
intriguing target for novel therapeutic intervention, and this is an active and rapidly 
expanding field of investigation. Inhibiting cancer cell ability to repair DNA in 
combination with chemo or radio-therapy treatment may render cancer treatment 
more potent; it may push tumor cells past a tolerable point or threshold of DNA 
damage and induce cell death, preventing further mutation, heterogeneity and the 
generation or outgrowth of resistant clones which leads to resistance on a tumor 
level. 
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 In addition, the same level of DNA repair which decreases the efficacy of 
cancer treatment can, through its inherently limited and often error prone nature, 
lead to continued mutation and increased genome variation [122]. Therefore, DNA 
repair activity in tumor cells is not only a direct source of resistance to chemo- and 
radio-therapy, but this same DNA repair functionality can promote continued 
mutation and heterogeneity as a direct result of its limited scope, and thus in-
directly lead to more robust and acquired drug resistance. 
I proposed that inhibiting proteins involved in DNA repair and maintenance 
(such as BRCA2) is a method to induce complementary lethality to DNA damage-
inducing chemotherapeutic drugs and enhance the probability of catastrophic and 
lethal toxicity in tumor cells. In the third chapter of this thesis I show that the 
induction of complementary lethality with combined targeting of DNA repair factors 
involved in cellular response to the mechanism of action of different drugs may be 
a potential strategy to improve cancer therapy (by overcoming innate resistance to 
treatment).  
I hypothesized that BRCA2 knockdown with siRNA would potentiate 
cisplatin and melphalan treatment because both drugs induce DSBs [52], and 
BRCA2 is an integral part of the complex responsible for HRR [123, 124].  My data 
support this assertion, which is in agreement with another study highlighting 
increased sensitivity to alkylating agents in BRCA2 knockout mice [21], and a 
report describing glioma cell sensitization to temozolomide following 
downregulation of BRCA2 and RAD51 [125].   
I was surprised to find that BRCA2 knockdown potentiated 5-FUdR toxicity, 
albeit to a much smaller degree than cisplatin and melphalan, but enough to fulfill 
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my definition of complementary lethality. I expected that BRCA2 knockdown would 
have no effect on 5-FUdR toxicity given the lack of effect with pemetrexed, and the 
apparently limited involvement of 5-FUdR in pathways that correspond with BRCA2 
function. BRCA2 does not appear directly related to the mechanism of action of 5-
FUdR since the drug targets TS. However, upsetting the balance of intracellular 
nucleotide pools through treatment with drugs like 5-FU can stall replication fork 
progression [126]. BRCA2 has been shown to maintain stability of stalled 
replication forks [49, 127] which may explain why BRCA2 knockdown potentiates 
the activity of 5-FUdR. This, however, may not be the primary function of BRCA2 
or 5-FUdR in the cell, which may explain why the potentiation of 5-FUdR was 
relatively minor. 
As expected from previously-published work, TS downregulation 
potentiated the effects of both 5-FUdR and pemetrexed. This may in large part be 
due to the fact that knockdown of TS mRNA in combination with pharmacological 
inhibition of TS protein are complementary functions [58, 128]. TS siRNA, however, 
did not appear to induce complementary lethality to either cisplatin or melphalan, 
suggesting that TS is not intimately involved in cellular response to those drugs. 
Cumulatively, these results suggest that BRCA2 and TS are involved in 
resistance to different classes of drugs, and that they may be involved in largely 
separate pathways within the cell. The cell cycle data further supports this 
assertion because it shows that BRCA2 and TS downregulation differentially 
affects cell cycle progression and that simultaneously targeting both factors has 
the potential to induce two discrete blocks in cell cycle. This renders an anti-BRCA2 
and anti-TS combination therapy particularly intriguing from an acquired resistance 
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perspective, since mathematical modelling and clinical data has established that 
the probability of resistance decreases with the number of targets and drugs in a 
particular treatment [12]. It would be interesting to determine mathematically what 
the probability of resistance to combined siRNA and combined drug treatment 
would be, and is something I hope to do on a collaborative basis in the future.    
Simultaneous downregulation of BRCA2 and TS potentiated the effects of 
all four tested drugs, thus creating multi-drug sensitive tumors. These experiments 
demonstrated that tumors can be sensitized to different classes of 
chemotherapeutics by targeting separate factors critical to cellular response to 
those drugs. An important determination was that there were no antagonistic 
effects observed during combined siRNA treatment. These findings are particularly 
germane in the context of chemotherapy, because drugs are rarely administered 
in isolation [129].  
I tested whether combined complementary lethality to two drugs could be 
achieved simultaneously in the same cell population, because this would be most 
closely related to current and future clinical scenarios. An important point to 
consider is that differential pharmacokinetic and pharmacodynamic factors 
relevant to different drugs result in unequal uptake into tumor cells; that is, cells in 
different locations within tumors, and at different sites in the body, are likely to be 
accessible to different drugs in different ways [130, 131]. Since tumor cells may 
take up drugs at rates different from those administered (and some drugs may 
accumulate in tumors at low concentrations that are difficult to predict or plan for) 
then sensitizing tumor cells to all drugs in a treatment cocktail can be an advantage. 
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The proposed treatment with combined siRNAs targeting multiple mRNAs to 
induce complementary lethality to different drugs may have this desirable affect.  
 Interestingly, I observed some apparent antagonism when cisplatin and 
pemetrexed were used in a combined treatment, and antisense mediated 
complementary lethality was not as effective in this treatment group. These results 
have potential implications for therapy because cisplatin and pemetrexed 
combinations are currently used to treat a variety of different cancers, including 
non-small cell lung cancer (NSCLC) [132].  
The induction of complementary lethality in the context of DNA repair 
provides an alternative perspective to the focus on personalized medicine in cancer 
therapy. It contrasts with the idea of synthetic lethality, which relies upon identifying 
pre-existing deficiencies in cancer cell genomes and exploiting them for therapeutic 
benefit [67].  
A prototypical example of synthetic lethality with therapeutic applications is 
the discovery and development of PARP1 inhibitors, many of which have and are 
currently undergoing clinical trials with varying degrees of success [114, 133]. The 
key to this strategy however, is the identification of a pre-existing weakness (e.g., 
BRCA deficiency) in a cancer cell, and tailoring a therapy designed to exploit or 
exacerbate that vulnerability. In addition, the application of synthetic lethality in a 
heterogeneous tumor cell context renders resistance to therapy highly likely, 
because by definition only a certain subset of tumor cells with a particular mutation 
or alteration will be affected.  
Induction of complementary lethality via targeting DNA repair theoretically 
nullifies the need to understand the distinct genotype of a targeted tumor. Instead, 
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this concept relies on a unifying principle: the fact that tumors need to maintain a 
minimum level of genomic stability in order to survive, and that this must occur in 
the face of chemotherapy and radiation. Therefore, complementary lethality not 
only overcomes innate resistance to treatment, it may help to prevent the outgrowth 
of resistant clones by sensitizing all cells in a tumor to a particular therapy, instead 
of relying on pre-existing vulnerabilities within a heterogeneous population.    
 As a result of my studies into complementary lethality using siRNA in 
Chapter 3, I developed a BRCA2-targeting ASO candidate drug to specifically 
sensitize cancer cells to the effects of the DNA damaging agent cisplatin. Many 
candidate antisense oligodeoxynucleotide (ASO) based agents are currently 
undergoing various phases of clinical trials [134, 135]. Importantly, ASOs also 
exhibit several advantages over siRNAs for in vivo use, including increased stability 
in serum and decreased need for a delivery or carrier vehicle [29]. My rationale 
was based on the known role of BRCA2 in DNA repair and clinical data that 
individuals with BRCA2-mutated tumors respond more favorably to platinum-based 
chemotherapy. In addition, high levels of BRCA2 mRNA have been associated with 
poor patient prognosis [136]. Retrospective analysis of RNA-sequencing data 
revealed that BRCA2 mRNA is highly expressed in different types of human 
cancers (personal communication, Dr. Sherry Y. Wu), suggesting that BRCA2 may 
be a good target for an antisense-based drug directly targeting BRCA2 mRNA. 
 In order to better understand the role that BRCA2 inhibition may play in 
human patients, I performed TCGA database analysis which revealed that BRCA2 
mutations in endometrial and ovarian cancer provide a better survival benefit than 
BRCA1 mutations. Although the lack of correlation does not rule out possible 
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therapeutic advantages after inhibition of BRCA1 in patients with functional BRCA1 
genes, these data suggest that BRCA2 may be a more useful target for reduction. 
My analysis of human tumor sample data is in accord with previous reports that 
BRCA2 mutations may be beneficial for patient prognosis following drug treatment 
and/or radiotherapy [92, 102] and supports the potential of BRCA2 reduction to 
enhance patient survival. 
I showed that combining BRCA2 ASO and cisplatin treatment is an effective 
strategy to render different types of cancer cells more sensitive to the effects of 
DNA-damaging drugs. In particular, the ability of BRCA2 ASO treatment to reduce 
acquired cisplatin resistance in head and neck tumor cells is an important clinical 
finding, since a proportion of cancer patients eventually develop resistance to 
platinum-based chemotherapy [51]. 
 The fact that BRCA2 ASO did not greatly potentiate cisplatin treatment in 
non-cancerous HK-2 cells suggests that tumor cells may be more sensitive to this 
type of treatment regimen. I hypothesize this is due to differences in DNA integrity, 
however it remains to be determined whether this is the case, or if specific, 
common mutations in tumor cells predispose them to BRCA2 ASO mediated 
sensitization to cisplatin.  
 Furthermore, an emerging phenomenon is the development of treatment 
resistance in previously treatment-responsive BRCA2-mutated tumors. Such 
tumors can undergo reversion mutations that re-activate BRCA2 function and lead 
to treatment failure [75, 137]. The implications are twofold. First, it highlights the 
importance of BRCA2 function for tumor cell survival in the face of strong selection 
pressures such as cytotoxic drug treatment. Second, it suggests that BRCA2 ASO 
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treatment could be of benefit even in individuals with tumors composed primarily 
of cells harboring inactivating BRCA2 polymorphisms.   
 For the first time, I linked BRCA2 with cellular metabolic response following 
cisplatin treatment and showed that cellular respiration is negatively affected in 
cells treated with BRCA2 ASO and cisplatin. I was unable to detect a difference in 
mitochondrial function by MitoTracker staining, suggesting that the defect in 
respiration is either mitochondria-independent, or not related to changes in the 
number of functioning mitochondria per cell. Furthermore, I identified an increase 
in glucose uptake that did not result in increased glycolysis, nor did it prevent a 
decrease in cell adhesion. Therefore, this may be a marker of cell stress and a 
response by affected cells to generate additional energy necessary to deal with the 
results of this stress. Overall, these data suggest that BRCA2 helps to maintain 
cellular metabolic processes following cisplatin treatment and, after reduction of 
BRCA2, cisplatin induces respiratory collapse and a non-productive increase in 
glucose uptake.   
 Due to the clinical importance of metastatic disease, I determined the effect 
of my treatment regimen on metastatic frequency. I found that ASO-mediated 
reduction of BRCA2 combined with cisplatin treatment led to decreased human 
tumor cell metastatic frequency in a chick CAM model. Cisplatin may be particularly 
effective at preventing metastasis by cells without active BRCA2, which may be 
due to an enhanced capacity to reduce tumor cell proliferation/viability (as 
suggested by the in vitro experiments). However, the results of the experiments 
presented here do not distinguish among three possibilities: that the lower number 
of metastatic foci present in the CAM following combined BRCA2 ASO and 
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cisplatin treatment was due to decreased tumor cell viability, that the combined 
treatment decreased the ability of tumor cells to extravasate and survive in tissue 
surrounding blood vessels without decreasing tumor cell viability, or a combination 
of the two. Regardless, inhibition of BRCA2 may be a useful strategy to decrease 
metastatic burden in patients treated with cisplatin, because it decreases the innate 
resistance of cancer cells to this cytotoxic drug. In addition, cisplatin is not the only 
anti-cancer agent that  BRCA2 ASO treatment may improve, and the PARP1 
inhibitor olaparib holds intriguing promise for combination treatment with BRCA2 
knockdown (from both an innate resistance and acquired resistance perspective).   
Olaparib is approved for treatment of BRCA1/2-mutated ovarian tumors. 
However, this represents only a subset of cancer patients [69] and resistance can 
occur even in this population [75]. I tested the BRCA2 ASO in combination with 
olaparib to determine whether the combination could: 1) overcome innate 
resistance and increase the potential usefulness of olaparib by rendering HRR-
proficient, BRCA2-positive tumors sensitive to the drug, and 2) prevent acquired 
resistance in cell populations with mixed HRR-proficiency.  
 I showed, using human lung, ovarian, and breast cancer cell lines, that 
BRCA2 ASO treatment can overcome innate resistance to olaparib in these cell 
lines. None are reported to harbour BRCA2 or BRCA1 mutations (COSMIC CCLE 
database) [117] and, with functional BRCA2 capable of mediating HRR, are 
relatively resistant to the therapeutic effects of PARP1/2 inhibition by olaparib. 
Therefore, BRCA2 ASO treatment has the potential to render a higher proportion 
of tumor cells sensitive to olaparib treatment, which may extend the usefulness and 
applicability of this drug in the clinic. 
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 The fact that olaparib primarily targets HRR-deficient tumors is also a 
potential problem in terms of positive selection for resistant clones in a 
heterogeneous tumor ecosystem. Most solid human tumors exhibit complex 
polyclonal variability and data from single nucleus sequencing of breast tumors 
suggests that no two tumor cells are identical [9]. This renders resistance to 
targeted therapy and chemotherapy inevitable mathematically [12], and very 
common biologically [11, 18]. Several olaparib resistance mechanisms have 
already been described in this context, including the outgrowth of tumors with re-
activation mutations in BRCA2 which render olaparib ineffective [73]. In addition, 
BRCA1-mutated tumors cells with a concomitant mutation in 53BP1 are no longer 
HRR-deficient and also exhibit resistance to PARP1 inhibition [138]. It therefore 
appears that olaparib treatment will fail at high frequency without any 
corresponding positive selection pressure for cells with HRR-deficiency.  
Combining BRCA2 inhibition with PARP1 inhibition can achieve a state 
where each individual treatment positively selects for cells with unique 
susceptibility to the other treatment, thus preventing or delaying resistance: this is 
the essence of the concept which I have termed reciprocal positive selection for 
weakness. The data from my mixed cell experiments suggests that simultaneous 
inhibition of BRCA2 and olaparib treatment has the ability to limit the proliferation 
of tumor cells heterogeneous for HRR-proficiency, thus preventing positive 
selection of resistant cells based on their underlying ability to repair DNA.  
An important consideration for the future is whether it is possible to develop 
resistance to simultaneous BRCA2 and PARP1 inhibition (either through a primary 
mechanism related to HRR, or a secondary mechanism unrelated to HRR-
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proficiency). It may be possible to address this question using a barcoded shRNA 
library to downregulate a large assortment of genes in the context of BRCA2 
deficiency and olaparib treatment. The shRNA barcode could be used to determine 
which gene or genes were down-regulated in any surviving cells. This experiment 
would divulge whether resistance to combined BRCA2 and PARP1 inhibition is 
possible, and if so, identify a subset of targets for further study and development 
of strategies to prevent or overcome this potential resistance mechanism.   
The in vivo data suggest that it is possible to combine BRCA2 inhibition and 
olaparib treatment for potential therapeutic benefit. The mice which received 
combination treatment exhibited the fewest tumor nodules, and the lowest tumor 
weight relative to control and each of the single treatments. In particular, the i.p 
model recapitulates several hallmarks of later stage ovarian cancer, and is a model 
to explore the potential of therapy to prevent the establishment of metastatic 
lesions at secondary sites in the peritoneal cavity [139]. This data suggests that 
combined BRCA2 downregulation and olaparib treatment may prevent spread and 
growth of ovarian tumours to secondary sites. Further experiments are needed to 
determine the capacity of BRCA2 ASO and olaparib treatment to extend the 
survival of mice harbouring ovarian tumors,  since the experiment described in this 
thesis was designed only to asses tumor growth, and did not determine overall or 
progression-free survival in the host mouse.   
Furthermore, to address the potential for treatment-mediated toxicity in vivo 
it will be necessary to use a mouse homograft model and inhibit BRCA2 using a 
sequence that targets mouse BRCA2. The in vivo experiments conducted during 
this thesis work utilized a human xenograft model, and the siRNA targeted human 
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BRCA2 (but not mouse BRCA2). As a result, the potential adverse effects of 
combined BRCA2 inhibition with olaparib treatment could not be investigated.   
In the future, to directly address the ability of BRCA2 ASO and olaparib 
treatment to prevent selection based on HRR proficiency in vivo, I propose utilizing 
a mixed tumor model that incorporates secreted luciferases to identify changes in 
population proportion. For this experiment, HRR-proficient (shControl) and 
deficient (shBRCA2) cells would be engineered to express secreted luciferases of 
different wavelengths, and this would enable real time monitoring of tumor 
proportion from blood draw [140]. Such an experiment would show, for the first 
time, whether resistance to olaparib can be prevented in a heterogenous tumor 
population by simultaneous inhibition of BRCA2 in vivo. 
In addition, immunotherapy is a burgeoning field of research in oncology, 
and numerous novel strategies to increase immune-mediated destruction of cancer 
cells are being developed. Tumors with a high mutational load produce 
immunogenic neo-antigens, which can potentially facilitate their elimination by the 
immune system [25, 141]. Lack of efficient DNA repair mechanisms can increase 
mutation load, and thus promote cyctotoxic T-lymphocyte (CTL) recognition of 
cancer cells [142]. A logical extension of this thesis research would be to test 
whether inhibition of BRCA2 function could lead to an increase in antigenic 
mutational load, and whether this increase could make tumors more immunogenic. 
It would be illuminating to combine BRCA2 inhibition with immune checkpoint 
blockade (either in the form of anti-CTLA4 or anti-PD1 antibodies) in an 
immunocompetent mouse model of breast or ovarian cancer, to determine whether 
anti-tumor CTL responses are increased.   
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